{"id":301,"date":"2020-06-01T17:33:07","date_gmt":"2020-06-01T08:33:07","guid":{"rendered":"https:\/\/gucvmed.med.gunma-u.ac.jp\/0_web\/?page_id=301"},"modified":"2020-06-01T18:09:08","modified_gmt":"2020-06-01T09:09:08","slug":"2017%e5%b9%b4%e7%a0%94%e7%a9%b6%e4%bc%9a%e3%83%bb%e8%ac%9b%e6%bc%94%e4%bc%9a","status":"publish","type":"page","link":"https:\/\/gucvmed.med.gunma-u.ac.jp\/?page_id=301","title":{"rendered":"2017\u5e74\u7814\u7a76\u4f1a\u30fb\u8b1b\u6f14\u4f1a"},"content":{"rendered":"<p><secton><\/secton><\/p>\n<h4>\u7b2c18\u56deAdvanced cardiac imaging laboratory(ACIL) 2017.1.7\uff08\u6771\u4eac\uff09<\/h4>\n<p>\u7b20\u9593\u3000\u5468<br \/>\n\u5fc3\u4e0d\u5168\u306b\u304a\u3051\u308bMIBG\u306e\u6709\u7528\u6027<\/p>\n<h4>\u7b2c232\u56de\u4e00\u822c\u5b9a\u671f\u5065\u5eb7\u8a3a\u65ad\u306b\u304a\u3051\u308b\u80f8\u90e8\u30ec\u30f3\u30c8\u30b2\u30f3\u5199\u771f\u306e\u8aad\u5f71\u8b1b\u5ea7\u30002017.1.13\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\u8302\u6728\u3000\u5145<\/p>\n<h4>\u7b2c29\u56de\u81e8\u5e8a\u4e0d\u6574\u8108\u7814\u7a76\u4f1a\u30002017.1.14\uff08\u6771\u4eac\uff09<\/h4>\n<p>1)\u91d1\u53e4\u5584\u660e<br \/>\n\u3010\u7279\u5225\u8b1b\u6f14\u3011Iesaka AT\u3001Yamabe AT\u3068\u65b0\u898fAVNRT\u3068\u306e\u95a2\u4fc2\u306b\u3064\u3044\u3066\u306e\u4e00\u8003\u5bdf\uff0e<\/p>\n<p>2)\u98ef\u585a\u8cb4\u58eb\u3001\u5165\u6c5f\u5fe0\u4fe1\u3001\u7530\u6751\u5cfb\u592a\u90de\u3001\u7530\u6751\u7f8e\u592e\u3001\u98ef\u5cf6\u8cb4\u53f2\u3001\u592a\u7530\u660c\u6a39\u3001\u9f4b\u85e4\u7ae0\u5b8f\u3001\u4e2d\u5cf6\u3000\u5fe0\u3001\u5009\u6797\u6b63\u5f66\u3001\u91d1\u53e4\u5584\u660e<br \/>\n\u51a0\u9759\u8108\u6d1e\u9060\u4f4d\u90e8\u3092\u6700\u65e9\u671f\u8208\u596e\u90e8\u4f4d\u306b\u6709\u3059\u308b\u304c\u3001\u53f3\u5074\u526f\u4f1d\u5c0e\u8def\u3092essential pathway\u3068\u3059\u308b\u3068\u8003\u3048\u3089\u308c\u305fAVRT\u306e\uff11\u4f8b\uff0e<\/p>\n<h4>\u547c\u5438\u5668\u79d1\u533b\u306eTotal Care\u30002017.1.20(\u524d\u6a4b)<\/h4>\n<p>\u5c0f\u677f\u6a4b\u7d00\u901a<br \/>\nDOAC\u3092\u7528\u3044\u305f\uff36\uff34\uff25\u6cbb\u7642<\/p>\n<h4>\u592a\u7530\u533b\u5e2b\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\u30002017.1.20(\u592a\u7530)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u5faa\u74b0\u5668\u75be\u60a3\u306b\u304a\u3051\u308b\u7761\u7720\u547c\u5438\u969c\u5bb3\u306e\u6cbb\u7642\u610f\u7fa9\u3068\u30c8\u30d4\u30c3\u30af\u30b9<\/p>\n<h4>\u7b2c36\u56de\u5927\u962a\u81e8\u5e8a\u96fb\u6c17\u751f\u7406\u30d5\u30a9\u30fc\u30e9\u30e0\u30002017.1.21\uff08\u5927\u962a\uff09<\/h4>\n<p>\u91d1\u53e4\u5584\u660e<br \/>\nsuperior slow pathway\u3068\u65b0\u3057\u3044\u623f\u5ba4\u7d50\u7bc0\u30ea\u30a8\u30f3\u30c8\u30ea\u30fc\u6027\u983b\u62cd\u306e\u63d0\u5531\uff0e<\/p>\n<h4>\u7b2c14\u56deCirculation\u30df\u30fc\u30c6\u30a3\u30f3\u30b0\u30002017.1.23(\u6d45\u8349)<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\n\u7cd6\u5c3f\u75c5\u306e\u5408\u4f75\u75c7\u4e88\u9632\u306f\u65b0\u305f\u306a\u30b9\u30c6\u30fc\u30b8\u3078<\/p>\n<h4>\u6b66\u7530\u793e\u5185\u8b1b\u6f14\u4f1a\u30002017.1.23\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u5faa\u74b0\u5668\u75be\u60a3\u306b\u304a\u3051\u308b\u7761\u7720\u547c\u5438\u969c\u5bb3\u306e\u6cbb\u7642\u610f\u7fa9\u3068\u30c8\u30d4\u30c3\u30af\u30b9<\/p>\n<h4>\u7fa4\u99ac\u770c\u75c5\u9662\u5354\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\u30002017.1.23\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u8239\u7530\u7adc\u4e00<br \/>\n\u51a0\u52d5\u8108\u30fb\u672b\u68a2\u8840\u7ba1\u30fb\u80ba\u52d5\u8108\u30a4\u30f3\u30bf\u30fc\u30d9\u30f3\u30b7\u30e7\u30f3\u306e\u6700\u524d\u7dda\uff5e\u6297\u8840\u6813\u7642\u6cd5\u306e\u77e5\u898b\u3092\u3075\u307e\u3048\u3066\uff5e<\/p>\n<h4>\u7fa4\u99ac\u51a0\u52d5\u8108\u75be\u60a3\u8b1b\u6f14\u4f1a\uff5e\u51a0\u52d5\u8108\u75be\u60a3\u4e88\u9632\u306eNew Stage\uff5e\u30002017.1.24\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u5927\u5c71\u5584\u662d<br \/>\nFH\u306e\u8a3a\u65ad\u3068\u6cbb\u7642<\/p>\n<h4>\u30b5\u30ce\u30d5\u30a3\u30fc\u682a\u5f0f\u4f1a\u793e\u793e\u5185\u8b1b\u6f14\u30002017.1.25\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u8239\u7530\u7adc\u4e00<br \/>\n\u8102\u8cea\u4f4e\u4e0b\u7642\u6cd5\u306e\u6709\u7528\u6027\u3092\u63a2\u308b<\/p>\n<h4>\u7fa4\u99acBPH\u30d5\u30a9\u30fc\u30e9\u30e0\u30002017.1.26(\u524d\u6a4b)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\nPEDE-5\u963b\u5bb3\u85ac\u306e\u5b89\u5168\u6027\u306b\u3064\u3044\u3066<\/p>\n<h4>\u6b66\u7530\u85ac\u54c1\u682a\u5f0f\u4f1a\u793e\u793e\u5185\u8b1b\u6f14\u30002017.1.30\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u8239\u7530\u7adc\u4e00<br \/>\nPCI\u5f8c\u306e\u85ac\u7269\u7642\u6cd5<\/p>\n<h4>\u30d0\u30a4\u30a8\u30eb\u793e\u5185\u8b1b\u6f14\u4f1a\u30002017.1.30(\u524d\u6a4b)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u5faa\u74b0\u5668\u8a3a\u7642\u306eUP TO DATE<\/p>\n<h4>\u7fa4\u99ac\u7761\u7720\u6642\u547c\u5438\u969c\u5bb3\u7814\u7a76\u4f1a\u3000\u7b2c13\u56de\u5b66\u8853\u96c6\u4f1a\u30002017.2.2\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u5faa\u74b0\u5668\u9818\u57df\u306b\u304a\u3051\u308b\u967d\u5727\u6cbb\u7642\u306e\u73fe\u72b6<\/p>\n<h4>\u65ed\u8102\u8cea\u7570\u5e38\u75c7\u30d5\u30a9\u30fc\u30e9\u30e0\u30002017.2.3\u3000(\u5343\u8449)<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\n\u8102\u8cea\u304b\u3089\u5faa\u74b0\u5668\u75be\u60a3\u3092\u8a3a\u308b\uff5e\u6700\u65b0\u306e\u77e5\u898b\u3092\u8e0f\u307e\u3048\u3066\uff5e<\/p>\n<h4>\u7b2c1\u56de\u685c\u5c71Arrhythmia Meeting\u30012017.2.3\uff08\u540d\u53e4\u5c4b\uff09<\/h4>\n<p>\u91d1\u53e4\u5584\u660e<br \/>\nsuperior slow pathway\u3068\u65b0\u3057\u3044\u623f\u5ba4\u7d50\u7bc0\u30ea\u30a8\u30f3\u30c8\u30ea\u30fc\u6027\u983b\u62cd\u306e\u63d0\u5531\uff0e<\/p>\n<h4>\u9759\u8108\u8840\u6813\u585e\u6813\u75c7conference in\u3000\u9928\u67972017.2.6\uff08\u9928\u6797\uff09<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\nPE\/DVT\u306e\u30d1\u30e9\u30c0\u30a4\u30e0\u30b7\u30d5\u30c8<\/p>\n<h4>\u6162\u6027\u5fc3\u4e0d\u5168\u6cbb\u7642\u30bb\u30df\u30ca\u30fc\u30002017.2.6\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u7b20\u9593\u3000\u5468<br \/>\n\u4e88\u5f8c\u3092\u898b\u636e\u3048\u305f\u5229\u5c3f\u5264\u306e\u4f7f\u3044\u65b9<br \/>\n-\u5fc3\u81d3\u4ea4\u611f\u795e\u7d4c\u6a5f\u80fd\u306b\u53ca\u307c\u3059\u5f71\u97ff\u304b\u3089\u8003\u5bdf\u3059\u308b<\/p>\n<h4>\u7b2c233\u56de\u4e00\u822c\u5b9a\u671f\u5065\u5eb7\u8a3a\u65ad\u306b\u304a\u3051\u308b\u80f8\u90e8\u30ec\u30f3\u30c8\u30b2\u30f3\u5199\u771f\u306e\u8aad\u5f71\u8b1b\u5ea7\u30002017.2.8\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\u8302\u6728\u3000\u5145<\/p>\n<h4>\u7b2c54\u56de\u6e6f\u5cf6\u4e0d\u6574\u8108\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b92017.2.10\uff08\u6771\u4eac\uff09<\/h4>\n<p>\u91d1\u53e4\u5584\u660e<br \/>\nsuperior slow pathway\u3068\u65b0\u3057\u3044\u623f\u5ba4\u7d50\u7bc0\u30ea\u30a8\u30f3\u30c8\u30ea\u30fc\u6027\u983b\u62cd\u306e\u63d0\u5531\uff0e<\/p>\n<h4>Diabetes total care seminar\uff5e\u7cd6\u5c3f\u75c5\u6cbb\u7642\u306e\u65b0\u305f\u306a\u53ef\u80fd\u6027\uff5e2017.2.10\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u4f34\u91ce\u6f64\u4e00<br \/>\n\u7cd6\u5c3f\u75c5\u3092\u5408\u4f75\u3057\u305f\u5fc3\u75be\u60a3\u60a3\u8005\u306e\u904b\u52d5\u7642\u6cd5\u306b\u3064\u3044\u3066<\/p>\n<h4>\u85e4\u5ca1\u591a\u91ce\u5730\u57df\u533b\u7642\u9023\u643a\u8b1b\u6f14\u4f1a\u30002017.2.13(\u85e4\u5ca1)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u5faa\u74b0\u5668\u9818\u57df\u306b\u304a\u3051\u308b\u30c8\u30d4\u30c3\u30af\u30fcENGAGE taial\u3068ASV\u6cbb\u7642\u306b\u3064\u3044\u3066\u30fc<\/p>\n<h4>\u7b2c8\u56deTsuchiura Arrhythmia Forum\u30002017.2.14\uff08\u571f\u6d66\uff09<\/h4>\n<p>\u91d1\u53e4\u5584\u660e<br \/>\n\u623f\u5ba4\u7d50\u7bc0\u95a2\u9023\u983b\u62cd\u306e\u6e29\u6545\u77e5\u65b0\uff0e<\/p>\n<h4>The Expert Comference of Arrhythmia in Nagoya vol.7\u30002017.2.15\uff08\u540d\u53e4\u5c4b\uff09<\/h4>\n<p>\u91d1\u53e4\u5584\u660e\uff1a<br \/>\nIesaka AT, Yamabe AT\u3068\u65b0\u898fAVNRT\u3068\u306e\u95a2\u4fc2\u306b\u3064\u3044\u3066\u306e\u4e00\u8003\u5bdf\uff0e<\/p>\n<h4>\u7b2c\uff19\u56de\u5faa\u74b0\u30fb\u4ee3\u8b1d\u30fb\u708e\u75c7\u30fb\u75c5\u614b\u7814\u7a76\u30bb\u30df\u30ca\u30fc\u3000\uff12\uff10\uff11\uff17.2.17(\u524d\u6a4b)<\/h4>\n<p>\u5c0f\u677f\u6a4b\u7d00\u901a<br \/>\nDOAC\u3092\u7528\u3044\u305fVTE\u6cbb\u7642\uff08\u4eee\uff09<\/p>\n<h4>\u4e09\u56fd\u5ce0PAH\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9\u30002017.2.17(\u524d\u6a4b)<\/h4>\n<p>\uff11\uff09\u9ad8\u9593\u5178\u660e<br \/>\n\u7fa4\u99ac\u5927\u5b66\u533b\u5b66\u90e8\u9644\u5c5e\u75c5\u9662\u306b\u304a\u3051\u308bPAH\u6cbb\u7642\u306e\u53d6\u308a\u7d44\u307f<\/p>\n<p>\uff12\uff09\u53cd\u753a\u79c0\u7f8e<br \/>\n\u75c7\u4f8b\u63d0\u793a<\/p>\n<p>\uff13\uff09\u91d1\u4e95\u7531\u9999\u3001\u91ce\u5cf6\u7be4\u5b50<br \/>\n\u30a8\u30dd\u30d7\u30ed\u30b9\u30c6\u30ce\u30fc\u30eb\u5c0e\u5165\u60a3\u8005\u69d8\u306e\u770b\u8b77\u30b1\u30a2\u306e\u5b9f\u969b<\/p>\n<h4>\u5e73\u621028\u5e74\u5ea6\u7b2c\uff13\u56de\u7fa4\u99ac\u770c\u96e3\u75c5\u6307\u5b9a\u533b\u7814\u4fee\u4f1a\u30002017.2.19(\u524d\u6a4b)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u6307\u5b9a\u96e3\u75c5\u306b\u304a\u3051\u308b\u5faa\u74b0\u5668\u30fb\u547c\u5438\u5668\u7cfb\u75be\u60a3\u306b\u95a2\u3059\u308b\u4ee3\u8868\u7684\u306a\u75be\u60a3\u306e\u8a3a\u65ad\u7b49<\/p>\n<h4>\u5fc3\u4e0d\u5168\u6cbb\u7642Up to Date\u30002017.2.20\uff08\u8328\u57ce\u770c\u7b20\u9593\u5e02\uff09<\/h4>\n<p>\u7b20\u9593\u3000\u5468<br \/>\n\uff5eSGLT2\u963b\u5bb3\u85ac\u304c\u3082\u305f\u3089\u3059\u53ef\u80fd\u6027\u3092\u542b\u3081\u3066\uff5e<\/p>\n<h4>\u7b2c3\u56deToyota Arrhythmia Comference\u30002017.2.24\uff08\u8c4a\u7530\uff09<\/h4>\n<p>\u91d1\u53e4\u5584\u660e<br \/>\nIesaka AT, Yamabe AT\u3068\u65b0\u898fAVNRT\u3068\u306e\u95a2\u4fc2\u306b\u3064\u3044\u3066\u306e\u4e00\u8003\u5bdf\uff0e<\/p>\n<h4>\u7b2c19\u56deAdvanced cardiac imaging laboratory(ACIL) \u30002017.2.25\uff08\u6771\u4eac\uff09<\/h4>\n<p>\u7b20\u9593\u3000\u5468<br \/>\nDPC\u3068\u5fc3\u81d3\u6838\u533b\u5b66<\/p>\n<h4>2016\u5e74\u65e5\u672c\u5fc3\u81d3\u8ca1\u56e3\u3001\u30d5\u30a3\u30ea\u30c3\u30d7\u30b9\u5fc3\u4e0d\u5168\u967d\u5727\u6cbb\u7642\u7814\u7a76\u5968\u52b1\u8cde\u30fb\u767a\u8868\u8cde\u30002017.2.25\uff08\u540d\u53e4\u5c4b\uff09<\/h4>\n<p>\u6885\u5c71\u3000\u6566<br \/>\nComparison with SERVE-HF trial about adaptive serbo bentilation therapy for patients with heart failure and central sleep apnea(ESC2016)<\/p>\n<h4>\u7b2c\uff13\u56deG-VTE\u7814\u7a76\u4f1a\u30002017.3.3(\u524d\u6a4b)<\/h4>\n<p>\u5c0f\u677f\u6a4b\u7d00\u901a<br \/>\n\u9759\u8108\u8840\u6813\u585e\u6813\u75c7\u6cbb\u7642\u306b\u304a\u3051\u308b\u521d\u671f\u5f37\u5316\u7642\u6cd5\u306e\u30a4\u30f3\u30d1\u30af\u30c8<\/p>\n<h4>\u5c71\u5f62\u5730\u533a\u65e5\u672c\u5fc3\u81d3\u6838\u5730\u57df\u5225\u7814\u4fee\u4f1a\u30002017.3.3\uff08\u5c71\u5f62\uff09<\/h4>\n<p>\u7b20\u9593\u3000\u5468<br \/>\n\u5fc3\u7b4b\u8840\u6d41SPECT<br \/>\n\uff5e\u8aad\u5f71\u306e\u57fa\u790e\u3068\u81e8\u5e8a\uff5e<\/p>\n<h4>\u7b2c22\u56de\u5c71\u5f62\u5fc3\u6838\u61c7\u8a71\u4f1a\u30002017.3.4\uff08\u5c71\u5f62\uff09<\/h4>\n<p>\u7b20\u9593\u3000\u5468<br \/>\n\u5faa\u74b0\u5668\u65e5\u5e38\u8a3a\u7642\u306b\u304a\u3051\u308b\u5fc3\u81d3\u4ea4\u611f\u795e\u7d4c\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u306e\u6709\u7528\u6027<\/p>\n<h4>\u5e73\u6210\uff12\uff18\u5e74\u5ea6\u7b2c\uff14\u56de\u7fa4\u99ac\u770c\u96e3\u75c5\u6307\u5b9a\u533b\u7814\u4fee\u4f1a\u30002017.3.5\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u6307\u5b9a\u96e3\u75c5\u306b\u304a\u3051\u308b\u5faa\u74b0\u5668\u30fb\u547c\u5438\u5668\u7cfb\u75be\u60a3\u306b\u95a2\u3059\u308b\u4ee3\u8868\u7684\u306a\u75be\u60a3\u306e\u8a3a\u65ad\u7b49<\/p>\n<h4>\u7b2c3\u56de\u7fa4\u99ac\u5185\u79d1\u6551\u6025\u6cbb\u7642\u7814\u7a76\u4f1a\uff08G-MECC\uff09\u30002017.3.6\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u6885\u5c71\u3000\u6566<br \/>\nPCAS(ACS\u306b\u3088\u308bVF survivio)\u306e2\u75c7\u4f8b<\/p>\n<h4>\u9928\u6797\u5e02\u9091\u697d\u90e1\u533b\u5e2b\u4f1a\u8b1b\u6f14\u4f1a\u30002017.3.9\uff08\u9928\u6797\uff09<\/h4>\n<p>\u6e05\u6c34\u5cb3\u4e45<br \/>\n\u5f53\u9662\u306b\u304a\u3051\u308b\u7cd6\u5c3f\u75c5\u6cbb\u7642\uff5e\u8840\u7ba1\u5408\u4f75\u75c7\u306e\u6cbb\u7642\u3068\u6559\u80b2\u5165\u9662\u30d1\u30b9\u5c0e\u5165\u306e\u8a66\u307f\uff5e<\/p>\n<h4>\u7fa4\u99ac\u770cCTEPH-BPA\u30d5\u30a9\u30fc\u30e9\u30e0\u30002017.3.10\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u8239\u7530\u7adc\u4e00<br \/>\n\u6551\u547d\u3057\u3048\u305f\u91cd\u75c7CTEPH\u306e\uff11\u4f8b<\/p>\n<h4>\u7b2c234\u56de\u4e00\u822c\u5b9a\u671f\u5065\u5eb7\u8a3a\u65ad\u306b\u304a\u3051\u308b\u80f8\u90e8\u30ec\u30f3\u30c8\u30b2\u30f3\u5199\u771f\u306e\u8aad\u5f71\u8b1b\u5ea7\u30002017.3.13\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\u8302\u6728\u3000\u5145<\/p>\n<h4>\u6771\u6bdb\u51a0\u52d5\u8108\u75be\u60a3\u8b1b\u6f14\u4f1a\uff5e\u51a0\u52d5\u8108\u75be\u60a3\u4e88\u9632\u306eNew Stage\uff5e\u30002017.3.22\uff08\u592a\u7530\uff09<\/h4>\n<p>\u6e05\u6c34\u5cb3\u4e45<br \/>\n\u865a\u8840\u6027\u5fc3\u75be\u60a3\u3092\u6709\u3059\u308b\u8102\u8cea\u7570\u5e38\u75c7\u60a3\u8005\u306e\u8abf\u67fb\uff5e\u5f53\u5730\u57df\u306b\u304a\u3051\u308b\u8a3a\u7642\u7d4c\u53e3\u3068\u6f5c\u5728\u7684\u306aFH\u60a3\u8005\u306e\u5b58\u5728\uff5e<\/p>\n<h4>\u7b2c12\u56de\u524d\u6a4b\u5730\u533a\u5faa\u74b0\u5668\u5185\u79d1\u30df\u30fc\u30c6\u30a3\u30f3\u30b0\u30002017.3.22(\u524d\u6a4b)<\/h4>\n<p>\u677e\u5c3e\u5f25\u679d<br \/>\nSHD intervention-what\u2019s next?<\/p>\n<h4>\u85ac\u5e2b\u5bfa\u52d5\u8108\u786c\u5316\u6027\u75be\u60a3\u30d5\u30a9\u30fc\u30e9\u30e02017\u30002017.3.27(\u6803\u6728)<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\n\u52d5\u8108\u786c\u5316\uff1a\u904e\u53bb\u3001\u73fe\u5728\u3001\u305d\u3057\u3066\u672a\u6765<\/p>\n<h4>\u7cd6\u5c3f\u75c5\u5408\u4f75\u75c7\u3092\u8003\u3048\u308b\u30002017.3.29(\u57fc\u7389)<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\n\u7cd6\u5c3f\u75c5\u60a3\u8005\u306e\u5faa\u74b0\u5668\u5408\u4f75\u75c7\u4e88\u9632\u306f\u65b0\u305f\u306a\u30b9\u30c6\u30fc\u30b8\u3078<\/p>\n<h4>\u4e0d\u6574\u8108\u30ec\u30af\u30c1\u30e3\u30fc in Himeji\u30002017.3.30\uff08\u59eb\u8def\uff09<\/h4>\n<p>\u91d1\u53e4\u5584\u660e<br \/>\nSuperior slow pathway\u3068\u65b0\u3057\u3044\u623f\u5ba4\u7d50\u7bc0\u30ea\u30a8\u30f3\u30c8\u30ea\u30fc\u6027\u983b\u62cd\u306e\u63d0\u5531<\/p>\n<h4>\u7b2c29\u56de\u4e21\u6bdb\u4e0d\u6574\u8108\u30bb\u30df\u30ca\u30fc\u30002017.4.8\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\u98ef\u585a\u8cb4\u58eb\u3001\u5165\u6c5f\u5fe0\u4fe1\u3001\u7530\u6751\u5cfb\u592a\u90ce\u3001\u7530\u6751\u672a\u592e\u3001\u98ef\u5cf6\u8cb4\u53f2\u3001\u592a\u7530\u660c\u6a39\u3001\u9f4b\u85e4\u7ae0\u5b8f\u3001\u4e2d\u5cf6\u3000\u5fe0\u3001\u5009\u6797\u6b63\u5f66\u3001\u91d1\u53e4\u5584\u660e<br \/>\nLinking \u6a5f\u5e8f\u306b\u3088\u308a\u7279\u7570\u306a\u5ba4\u623f\u4f1d\u5c0e\u69d8\u5f0f\u3092\u5448\u3057\u305fconcealed nodofascicular pathway \u3092\u4ecb\u3059\u308b\u623f\u5ba4\u30ea\u30a8\u30f3\u30c8\u30ea\u30fc\u6027\u983b\u62cd\u306e\u4e00\u4f8b\uff0e<\/p>\n<h4>ASV\u7279\u5225\u8b1b\u6f14\u4f1a\u30002017.4.8(\u677e\u672c)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u73fe\u72b6\u3067\u3044\u304b\u306bASV\u3092\u7528\u3044\u305f\u5fc3\u4e0d\u5168\u6cbb\u7642\u3092\u884c\u3046\u3079\u304d\u306a\u306e\u304b\uff1f<\/p>\n<h4>T2DM Forum in\u3000\u9577\u91ce\u30002017.4.11(\u9577\u91ce)<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\n\u7cd6\u5c3f\u75c5\u8a3a\u7642\u306e\u30cb\u30e5\u30fc\u30d1\u30e9\u30c0\u30a4\u30e0\uff5e\u5faa\u74b0\u5668\u5185\u79d1\u533b\u306e\u8996\u70b9\u304b\u3089\uff5e<\/p>\n<h4>\u6625\u65e5\u90e8\u5e02\u85ac\u5264\u5e2b\u4f1a\u7814\u4fee\u30bb\u30df\u30ca\u30fc\u30002017.4.13\uff08\u57fc\u7389\uff09<\/h4>\n<p>\u9752\u6728\u5eb7\u5f18<br \/>\n\u5f53\u9662\u306e\u5438\u5165\u7642\u6cd5\u652f\u63f4\u4f53\u5236\u3068\u5730\u57df\u306e\u53d6\u308a\u7d44\u307f<\/p>\n<h4>\u7b2c11\u56de\u6771\u4eacEP\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9\u304b\u3089\uff0d\u30e1\u30ab\u30cb\u30ba\u30e0\u3092\u8003\u3048\u308b\uff0d\u30002017.\uff14.15\uff08\u6771\u4eac\uff09<\/h4>\n<p>\u98ef\u585a\u8cb4\u58eb\u3001\u5165\u6c5f\u5fe0\u4fe1\u3001\u7530\u6751\u5cfb\u592a\u90ce\u3001\u7530\u6751\u672a\u592e\u3001\u98ef\u5cf6\u8cb4\u53f2\u3001\u592a\u7530\u660c\u6a39\u3001\u9f4b\u85e4\u7ae0\u5b8f\u3001\u4e2d\u5cf6\u3000\u5fe0\u3001\u5009\u6797\u6b63\u5f66\u3001\u91d1\u53e4\u5584\u660e<br \/>\nLinking \u6a5f\u5e8f\u306b\u3088\u308a\u7279\u7570\u306a\u5ba4\u623f\u4f1d\u5c0e\u69d8\u5f0f\u3092\u5448\u3057\u305fconcealed nodofascicular pathway \u3092\u4ecb\u3059\u308b\u623f\u5ba4\u30ea\u30a8\u30f3\u30c8\u30ea\u30fc\u6027\u983b\u62cd\u306e\u4e00\u4f8b<\/p>\n<h4>\u65e5\u672c\u65b0\u85ac\u793e\u5185\u8b1b\u6f14\u4f1a\u30002017.4.17(\u524d\u6a4b)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u5f53\u9662\u306b\u304a\u3051\u308b\u91cd\u75c7\u80ba\u9ad8\u8840\u5727\u6cbb\u7642\u306e\u53d6\u308a\u7d44\u307f-\u91cd\u75c7\u4f8b\u304b\u3089\u307f\u308b\u5371\u967a\u56e0\u5b50\u306e\u691c\u8a0e-<\/p>\n<h4>\u7b2c18\u56de\u7fa4\u99ac\u751f\u6d3b\u7fd2\u6163\u75c5\u30d5\u30a9\u30fc\u30e9\u30e0\u30002017.4.18(\u9ad8\u5d0e)<\/h4>\n<p>\u5b89\u9054\u4ec1<br \/>\n\u7cd6\u5c3f\u75c5\u60a3\u8005\u306e\u814e\u81d3\u30ea\u30cf\u30d3\u30ea\u30c6\u30fc\u30b7\u30e7\u30f3<\/p>\n<h4>T2DM Forum in Matsumoto\u30002017.4.21(\u677e\u672c)<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\n\u7cd6\u5c3f\u75c5\u8a3a\u7642\u306e\u30cb\u30e5\u30fc\u30d1\u30e9\u30c0\u30a4\u30e0\uff5e\u5faa\u74b0\u5668\u5185\u79d1\u533b\u306e\u8996\u70b9\u304b\u3089\uff5e<\/p>\n<h4>ATIS\u60a3\u8005\u306e\u8102\u8cea\u7570\u5e38\u75c7\u6cbb\u7642\u3068\u533b\u7642\u7d4c\u6e08\u3092\u8003\u3048\u308b\u30002017.4.22\uff08\u6771\u4eac\uff09<\/h4>\n<p>\u8239\u7530\u7adc\u4e00<br \/>\nPAD\u9818\u57df\u306b\u304a\u3051\u308bATIS\u30cf\u30a4\u30ea\u30b9\u30af\u60a3\u8005\u3068\u306f\uff1f<\/p>\n<h4>\u5b66\u8853\u8b1b\u6f14\u4f1a<br \/>\n\uff5e\u816b\u760d\u514d\u75ab\u3067\u80ba\u764c\u6cbb\u7642\u304c\u3069\u3046\u304b\u308f\u3063\u3066\u304d\u3066\u3044\u308b\u304b\uff5e\u30002017.4.27\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>1) \u9ad8\u91ce\u5cfb\u4e00<br \/>\n\u5f53\u9662\u3067\u306e\u30aa\u30d7\u30b8\u30fc\u30dc\u4f7f\u7528\u7d4c\u9a13\u306b\u3064\u3044\u3066<\/p>\n<p>2) \u5317\u539f\u4fe1\u4ecb<br \/>\n\u5f53\u9662\u3067\u306eNSCLC PD-L1\u67d3\u8272\u306b\u95a2\u3057\u3066<\/p>\n<p>3) \u6e05\u6c34\u96c4\u81f3<br \/>\n\u5f53\u9662\u3067\u306e\u30aa\u30d7\u30b8\u30fc\u30dc\u4f7f\u7528\u7d4c\u9a13\u306b\u3064\u3044\u3066<\/p>\n<h4>\u6771\u90a6\u75c5\u9662\u8b1b\u6f14\u4f1a\u30002017.4.27(\u6850\u751f)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u5faa\u74b0\u5668\u9818\u57df\u306b\u304a\u3051\u308b\u30c8\u30d4\u30c3\u30af &#8211; ENGAGE traial\u3068ASV\u6cbb\u7642\u306b\u3064\u3044\u3066-<\/p>\n<h4>\u7b2c10\u56de\u7fa4\u99ac\u5fc3\u4e0d\u5168\u3068Vasopressin\u8b1b\u6f14\u4f1a\u30002017.4.28(\u524d\u6a4b)<\/h4>\n<p>1)\u53cd\u753a\u79c0\u7f8e<br \/>\n\u6025\u6027\u5fc3\u4e0d\u5168\u60a3\u8005\u306e\u30a8\u30b3\u30fc\u8a55\u4fa1\u304b\u3089\u306eTolvasptan\u306e\u5f71\u97ff\u306e\u691c\u8a0e(\u4eee)<\/p>\n<p>2)\u9ad8\u677e\u5bdb\u4eba<br \/>\n\u5fc3\u4e0d\u5168\u95a2\u9023\u306e\u6700\u8fd1\u306e\u8a71\u984c(\u4eee)<\/p>\n<h4>\u7b2c\uff19\u56de\u5b9f\u5730\u533b\u5bb6\u30df\u30fc\u30c6\u30a3\u30f3\u30b0\u30002017.5.9\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\uff11) \u3000\u5c0f\u5009\u9053\u90ce<br \/>\nSGLT2\u963b\u5bb3\u85ac\u306e\u6709\u7528\u6027<\/p>\n<p>\uff12) \u5c0f\u677f\u6a4b\u7d00\u901a<br \/>\n\u9759\u8108\u8840\u6813\u585e\u6813\u75c7\u306e\u8a3a\u65ad\u3068\u6cbb\u7642<\/p>\n<h4>T2DM Forum in \u7fa4\u99ac\u30002017.5.10\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\n\u7cd6\u5c3f\u75c5\u60a3\u8005\u306e\u5faa\u74b0\u5668\u5408\u4f75\u75c7\u4e88\u9632\u306f\u65b0\u305f\u306a\u30b9\u30c6\u30fc\u30b8\u3078<\/p>\n<h4>\u7b2c20\u56deAdvanced cardiac imaging laboratory(ACIL)\u30002017.5.13\uff08\u6771\u4eac\uff09<\/h4>\n<p>\u7b20\u9593\u3000\u5468<br \/>\n\u8ca0\u8377\u5fc3\u7b4b\u30b7\u30f3\u30c1\u30b0\u30e9\u30d5\u30a3\u306e\u30d4\u30c3\u30c8\u30d5\u30a9\u30fc\u30eb<\/p>\n<h4>\u7b2c90\u56de\u5fc3\u81d3\u75c5\u8b1b\u6f14\u4f1a2017.5.20\uff08\u4e09\u91cd\uff09<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\n\uff08\u4eee\uff09\u5faa\u74b0\u5668\u75be\u60a3\u3068\u547c\u5438\u5668\u75be\u60a3\u306e\u7dcf\u5408\u7684\u306a\u6cbb\u7642\u6226\u7565<\/p>\n<h4>T2DM Forum in \u7fa4\u99ac\u6771\u6bdb\u5730\u533a\u30002017.5.22\uff08\u592a\u7530\uff09<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\n\u7cd6\u5c3f\u75c5\u8a3a\u7642\u306e\u30cb\u30e5\u30fc\u30d1\u30e9\u30c0\u30a4\u30e0\uff5e\u5faa\u74b0\u5668\u5185\u79d1\u533b\u306e\u8996\u70b9\u304b\u3089\uff5e<\/p>\n<h4>\u7b2c\u4e8c\u56de\u900f\u6790\u95a2\u9023\u5faa\u74b0\u5668\u30bb\u30df\u30ca\u30fc\u30002017.5.23(\u524d\u6a4b)<\/h4>\n<p>\uff11\uff09 \u4f50\u85e4\u4e07\u57fa\u4eba<br \/>\n\u814e\u4e0d\u5168\u60a3\u8005\u306b\u304a\u3051\u308b\u5fc3\u81d3\u753b\u50cf\u8a3a\u65ad\u306e\u5f79\u5272<\/p>\n<p>\uff12\uff09 \u9ed2\u6ca2\u5e78\u55e3<br \/>\n\u900f\u6790\u60a3\u8005\u3068\u5927\u52d5\u8108\u5f01\u72ed\u7a84\u75c7<\/p>\n<h4>\u3055\u3044\u305f\u307e\u5598\u606f\u30fbCOPD\u30d5\u30a9\u30fc\u30e9\u30e02017\u30002017.5.24\uff08\u3055\u3044\u305f\u307e\uff09<\/h4>\n<p>\u9752\u6728\u5eb7\u5f18<br \/>\n\u30c7\u30d0\u30a4\u30b9\u9078\u629e\u3092\u8003\u616e\u3057\u305fCOPD\u6cbb\u7642<\/p>\n<h4>\u7b2c235\u56de\u4e00\u822c\u5b9a\u671f\u5065\u5eb7\u8a3a\u65ad\u306b\u304a\u3051\u308b\u80f8\u90e8\u30ec\u30f3\u30c8\u30b2\u30f3\u5199\u771f\u306e\u8aad\u5f71\u8b1b\u5ea7\u30002017.5.24(\u9ad8\u5d0e)<\/h4>\n<p>\u8302\u6728\u3000\u5145<\/p>\n<h4>\u76db\u5ca1\u5e02\u533b\u5e2b\u4f1a\u5185\u79d1\u533b\u4f1a\u8b1b\u6f14\u4f1a\u30002017.5.25(\u76db\u5ca1)<\/h4>\n<p>\u9752\u6728\u5eb7\u5f18<br \/>\nCOPD\u3068\u5438\u5165\u652f\u63f4\u301c\u533b\u5e2b\u304c\u884c\u3046\u5438\u5165\u652f\u63f4\u306e\u30b3\u30c4\u301c<\/p>\n<h4>Hyperlipidemia Forum in GUNMA\uff5e\u51a0\u52d5\u8108\u75be\u60a3\u4e88\u9632\u306eNew Stage\uff5e2017.5.26(\u524d\u6a4b)<\/h4>\n<p>\u5927\u5c71\u5584\u662d<br \/>\n\u8102\u8cea\u7ba1\u7406\u306e\u73fe\u72b6\u3068FH\u306e\u8a3a\u65ad\u3068\u6cbb\u7642<\/p>\n<h4>\u81e8\u5e8a\u533b\u306e\u305f\u3081\u306e\u7d71\u8a08\u30bb\u30df\u30ca\u30fc\uff5e\u8a3a\u7642\u306e\u4e2d\u3067\u51fa\u4f1a\u3046\u7d71\u8a08\u304b\u3089\u7814\u7a76\u8a08\u753b\u307e\u3067\uff5e\u30002017.5.27(\u524d\u6a4b)<\/h4>\n<p>\u85e4\u7530\u6674\u5eb7<br \/>\n\u8cea\u554f\u7968\u3092\u7528\u3044\u305f\u7814\u7a76\u306e\u89e3\u6790\u624b\u6cd5<\/p>\n<h4>\u7b2c47\u56de\u81e8\u5e8a\u5fc3\u81d3\u96fb\u6c17\u751f\u7406\u7814\u7a76\u4f1a\u30002017.5.27(\u6771\u4eac)<\/h4>\n<p>\u98ef\u585a\u8cb4\u58eb\u3001\u91d1\u53e4\u5584\u660e\u3001\u4e2d\u5cf6\u5fe0\u3001\u5165\u6c5f\u5fe0\u4fe1\u3001\u592a\u7530\u660c\u6a39\u3001\u98ef\u5cf6\u8cb4\u53f2\u3001\u7530\u6751\u672a\u592e\u3001\u7530\u6751\u5cfb\u592a\u90ce\u3001\u9f4b\u85e4\u7ae0\u5b8f\u3001\u5009\u6797\u6b63\u5f66<br \/>\n\u901a\u5e38\u306eslow pathway\u3092bystander pathway\u3068\u3059\u308bsuperior type fast-slow \u623f\u5ba4\u7d50\u7bc0\u30ea\u30a8\u30f3\u30c8\u30ea\u30fc\u6027\u983b\u62cd\u306e\u4e00\u4f8b\uff0e<\/p>\n<h4>\u5b66\u8853\u8b1b\u6f14\u4f1a\uff5e\u3053\u308c\u304b\u3089\u306e\u7cd6\u5c3f\u75c5\u6cbb\u7642\u3092\u8003\u3048\u308b\uff5e\u30002017.5.29\uff08\u524d\u6a4b\uff09<\/h4>\n<p>1\uff09 \u6e05\u6c34\u5cb3\u4e45<br \/>\n\uff08\u4eee\uff09\u5faa\u74b0\u5668\u5c02\u9580\u533b\u304b\u3089\u898b\u305f\u7cd6\u5c3f\u75c5\u6cbb\u7642<\/p>\n<p>2\uff09 \u5009\u6797\u6b63\u5f66<br \/>\n\u7cd6\u5c3f\u75c5\u8a3a\u7642\u306e\u30cb\u30e5\u30fc\u30d1\u30e9\u30c0\u30a4\u30e0\uff1d\u5faa\u74b0\u5668\u5185\u79d1\u533b\u306e\u8996\u70b9\u304b\u3089\uff5e<\/p>\n<h4>\u30d6\u30ea\u30b9\u30c8\u30eb\u5317\u95a2\u6771Web\u8b1b\u6f14\u4f1a\u30002017.5.29(\u9ad8\u5d0e)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u9759\u8108\u8840\u6813\u75c7\u306e\u6700\u65b0\u6cbb\u7642<\/p>\n<h4>5th Clinical Discussion for Heart Failure 2017.6.2\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\uff11\uff09 \u9ad8\u677e\u5bdb\u4eba<br \/>\n\u5f53\u9662\u306b\u304a\u3051\u308bSGLT2\u963b\u5bb3\u85ac\u306e\u4f7f\u7528\u7d4c\u9a13\uff08\u4eee\uff09<\/p>\n<p>\uff12\uff09 \u4f50\u91ce\u5e78\u6075<br \/>\n\u91cd\u75c7\u5fc3\u4e0d\u5168\u60a3\u8005\u306b\u304a\u3051\u308b\u5185\u670d\u306b\u3088\u308b\u30a2\u30d7\u30ed\u30fc\u30c1<\/p>\n<h4>T2DM Forum in\u3000\u6817\u539f\u30002017.6.2(\u5bae\u57ce)<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\n\u7cd6\u5c3f\u75c5\u8a3a\u7642\u306e\u30cb\u30e5\u30fc\u30d1\u30e9\u30c0\u30a4\u30e0\uff5e\u5faa\u74b0\u5668\u5185\u79d1\u533b\u306e\u8996\u70b9\u304b\u3089\uff5e<\/p>\n<h4>\u7b2c63\u56de\u7fa4\u99ac\u770c\u6838\u533b\u5b66\u7814\u7a76\u4f1a\u30002016.6.3\uff08\u7fa4\u99ac\u5927\u5b66\uff09<\/h4>\n<p>\u5f8c\u85e4\u6176\u5927\u3001\u7b20\u9593\u3000\u5468\u3001\u5009\u6797\u6b63\u5f66<br \/>\n\u30a2\u30bc\u30eb\u30cb\u30b8\u30d4\u30f3\u304c\u4e0e\u3048\u308b\u814e\u4ea4\u611f\u795e\u7d4c\u3078\u306e\u5f71\u97ff\uff1a123I-MIGB\u30b7\u30f3\u30c1\u30b0\u30e9\u30d5\u30a3\u306b\u3088\u308b\u691c\u8a0e<\/p>\n<h4>\u7b2c\uff12\u56de\u80ba\u9ad8\u8840\u5727\u80ba\u5faa\u74b0\u5b66\u4f1a\u30002017.6.3\uff08\u672d\u5e4c\uff09<\/h4>\n<p>\u4e2d\u91ce\u8003\u82f1<br \/>\n\u5f53\u9662\u306b\u304a\u3051\u308b\u80ba\u9ad8\u8840\u5727\u75c7\u306b\u5bfe\u3059\u308b\u30de\u30b7\u30c6\u30f3\u30bf\u30f3\u306e\u4f7f\u7528\u7d4c\u9a13<\/p>\n<h4>\u5c0f\u7530\u539f\u5faa\u74b0\u5668\u7814\u7a76\u4f1a\u7279\u5225\u8b1b\u6f14\u4f1a\uff08LA-SUMMIT(Lipid&amp;Anticoagulant terapy)\u30002017.6.6(\u5c0f\u7530\u539f)<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\nLDL-C\u4f4e\u4e0b\u7642\u6cd5\u306e\u9032\u6b69\u3068\u6b8b\u3055\u308c\u3066\u3044\u308b\u8ab2\u984c<\/p>\n<h4>\u7b2c6\u56de\u91cd\u75c7\u5fc3\u75be\u60a3\u30d5\u30ed\u30f3\u30c6\u30a3\u30a2\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9\u30002017.6.6\uff08\u6a2a\u6d5c\uff09<\/h4>\n<p>\u91d1\u53e4\u5584\u660e<br \/>\nsuperior type fast-slow AVNRT\u306e\u7279\u7570\u306a\u96fb\u6c17\u751f\u7406\u5b66\u7684\u7279\u6027\uff0e<\/p>\n<h4>ASV\u7279\u5225\u8b1b\u6f14\u4f1a\u30002017.6.9\uff08\u3042\u305a\u307f\u91ce\uff09<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u73fe\u72b6\u3067\u3044\u304b\u306bASV\u3092\u7528\u3044\u305f\u5fc3\u4e0d\u5168\u6cbb\u7642\u3092\u884c\u3046\u3079\u304d\u306a\u306e\u304b\uff1f<\/p>\n<h4>\u7b2c37\u56de\u65e5\u672c\u30db\u30eb\u30bf\u30fc\u30fb\u30ce\u30f3\u30a4\u30f3\u30d9\u30a4\u30b7\u30d6\u5fc3\u96fb\u5b66\u7814\u7a76\u4f1a\u3001\u30002017.6.10\uff08\u6771\u4eac\uff09<\/h4>\n<p>\u91d1\u53e4\u5584\u660e\u3001\u4e2d\u5cf6\u3000\u5fe0\u3001\u9ed2\u6ca2\u5e78\u55e3\u3001\u5009\u6797\u6b63\u5f66<br \/>\n\u5065\u5e38\u4f8b\u306b\u304a\u3051\u308bJ\u6ce2\u306e\u5b58\u5728\u306f\u5de6\u5ba4\u5fc3\u5c16\u90e8\u306e\u904e\u91cf\u306e\u975e\u7dfb\u5bc6\u5c64\u3068\u95a2\u9023\u3059\u308b\uff0e<\/p>\n<h4>\u7cf8\u9b5a\u5ddd\u5e02\u533b\u5e2b\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\u30002017.6.15\u3000(\u7cf8\u9b5a\u5ddd)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\nPE\/DVT\u306e\u30d1\u30e9\u30c0\u30a4\u30e0\u30b7\u30d5\u30c8<\/p>\n<h4>\u6df1\u8c37\u65e5\u8d64\u8b1b\u6f14\u4f1a\u30002017.6.16\uff08\u6df1\u8c37\uff09<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u65e5\u5e38\u8a3a\u7642\u306b\u6f5c\u3080\u80ba\u9ad8\u8840\u5727\u75c7\u3068\u60a3\u8005\u69d8\u306e\u30b1\u30a2\u3092\u8003\u3048\u308b\u4f1a in \u6df1\u8c37<\/p>\n<h4>\u5c71\u5f62\u770c\u7acb\u75c5\u9662\u30d5\u30a9\u30fc\u30e9\u30e0\u3000\u300cSHD, what&#8217;s next\u300d\u30006\u670816\u65e5\u3000\uff08\u5c71\u5f62\uff09<\/h4>\n<p>\u677e\u5c3e\u5f25\u679d<br \/>\nprocedural complication of left atrial appendage closure &#8211; characteristics of complication case<\/p>\n<h4>T2DM Forum in\u3000\u6d5c\u677e\u30002017.6.17(\u6d5c\u677e)<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\n\u7cd6\u5c3f\u75c5\u60a3\u8005\u306e\u5faa\u74b0\u5668\u5408\u4f75\u75c7\u4e88\u9632\u306f\u65b0\u305f\u306a\u30b9\u30c6\u30fc\u30b8\u3078<\/p>\n<h4>\u7b2c236\u56de\u4e00\u822c\u5b9a\u671f\u5065\u5eb7\u8a3a\u65ad\u306b\u304a\u3051\u308b\u80f8\u90e8\u30ec\u30f3\u30c8\u30b2\u30f3\u5199\u771f\u306e\u8aad\u5f71\u8b1b\u5ea7\u30002017.6.21\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\u8302\u6728\u3000\u5145<\/p>\n<h4>\u7b2c7\u56de\u95a2\u6771\u30a2\u30d6\u30ec\u30fc\u30b7\u30e7\u30f3\u30d5\u30ed\u30f3\u30c6\u30a3\u30a2\u30002017.6.24\uff08\u6771\u4eac\uff09<\/h4>\n<p>\u91d1\u53e4\u5584\u660e\u3001\u4e2d\u5cf6\u3000\u5fe0\u3001\u5165\u6c5f\u5fe0\u4fe1\u3001\u98ef\u585a\u8cb4\u58eb\u3001\u5009\u6797\u6b63\u5f66<br \/>\n\u4e09\u5c16\u5f01\u8f2a\u306b\u9032\u5c55\u3059\u308bsuperior slow pathway\u306e\u713c\u707c\u5f8c\u6162\u6027\u671f\u306b\u540c\u90e8\u8d77\u6e90\u306e\u5fc3\u623f\u983b\u62cd\u304c\u767a\u751f\u3057\u305f\u4e00\u4f8b\uff0e<\/p>\n<h4>\u7fa4\u99ac\u770c\u5185\u79d1\u533b\u4f1a\u7dcf\u4f1a\u3000\u5b66\u8853\u8b1b\u6f14\u4f1a\u30002017.6.24\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u7b20\u9593\u3000\u5468<br \/>\n\u4e88\u5f8c\u3092\u898b\u636e\u3048\u305f\u5fc3\u4e0d\u5168\u6cbb\u7642\u85ac\u306e\u4f7f\u3044\u65b9<br \/>\n\uff5e\u5fc3\u81d3\u4ea4\u611f\u795e\u7d4c\u6d3b\u6027\u306e\u89b3\u70b9\u304b\u3089\uff5e<\/p>\n<h4>\u57fc\u7389\u77f3\u5fc3\u4f1a\u75c5\u9662\u3000\u9662\u5185\u8b1b\u6f14\u4f1a\u30002017.6.26(\u72ed\u5c71)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u5faa\u74b0\u5668\u9818\u57df\u306b\u304a\u3051\u308b\u7761\u7720\u547c\u5438\u969c\u5bb3\u306b\u3064\u3044\u3066<\/p>\n<h4>G GIRLS\u30002017.6.30\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u571f\u5c4b\u5bdb\u5b50<br \/>\n\u5f53\u9662\u306eDOAC\u4f7f\u7528\u72b6\u6cc1<\/p>\n<h4>\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a\u3000\u7537\u5973\u5171\u540c\u53c2\u753b\u30d5\u30a9\u30fc\u30e9\u30e0\u3000\u300c\u7559\u5b66-\u5973\u6027\u7de8\u300d\u30002017.7.1\uff08\u9ad8\u677e\uff09<\/h4>\n<p>\u677e\u5c3e\u5f25\u679d<br \/>\n\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0<br \/>\nSingle high volume center experience with Perclose Proglide in real-world: analysis of various procedure, various sheath size, and anatomical considerlation in japanese<\/p>\n<h4>\u7b2c\uff15\u56de\u9752\u68ee\u770c\u7761\u7720CPAP\u30bb\u30df\u30ca\u30fc\u30002017.7.1\uff08\u9752\u68ee\uff09<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u5faa\u74b0\u5668\u9818\u57df\u306b\u304a\u3051\u308b\u7761\u7720\u547c\u5438\u969c\u5bb3\u306b\u3064\u3044\u3066~SERVE-HF\u8a66\u9a13\u4ee5\u964d\u306eASV\u6cbb\u7642\u306e\u73fe\u72b6~<\/p>\n<h4>4th Actelion Academic Forun on Pulmonary Hypertension 2017.7.2(\u4eac\u90fd)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\nImportance of home medical care for patient with serve pulmonary arterial hypertension<\/p>\n<h4>\u7b2c8\u56deCOPD\u7814\u7a76\u4f1a\u30002017.7.5\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\u8302\u6728\u3000\u5145<br \/>\n\u91cd\u75c7COPD\u60a3\u8005\u306e\u75c7\u4f8b\u691c\u8a0e\u3000\u547c\u5438\u30ea\u30cf\u30d3\u30ea\u30c6\u30fc\u30b7\u30e7\u30f3\u3068\u6804\u990a\u7642\u6cd5<\/p>\n<h4>\u904e\u8d8a\u80ba\u9ad8\u8840\u5727\u75c7\u8b1b\u6f14\u4f1a\u30002017.7.7\u3000(\u80ce\u5185)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u8eab\u8fd1\u306b\u6f5c\u3080\u80ba\u52d5\u8108\u6027\u80ba\u9ad8\u8840\u5727\u75c7\u306e\u8a3a\u65ad\u3068\u6cbb\u7642<\/p>\n<h4>CVIT\u7dcf\u4f1a\u30002017.7.6-8\u3000\uff08\u4eac\u90fd\uff09\u2193<\/h4>\n<p>\u677e\u5c3e\u5f25\u679d<br \/>\nnew devices and complications of left atrial appendage closure &#8211; option for stroke prevention in the atrial fibrillation<\/p>\n<h4>\u7b2c38\u56de\u51a0\u4e0d\u5168\u7814\u7a76\u4f1a\u3000\u308f\u304c\u56fd\u306e\u5faa\u74b0\u5668\u8a3a\u7642\u306e\u904e\u53bb\u30fb\u73fe\u5728\u30fb\u672a\u6765\u30002017.7.8\uff08\u6771\u4eac\uff09<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\n\uff1c\u65e5\u5e38\u8a3a\u7642\u306e\u30d4\u30c3\u30c8\u30db\u30fc\u30eb\u2015\u6e29\u6545\u77e5\u65b0\u2015\uff1e<br \/>\n\u9ad8\u9f62\u8005\u306b\u591a\u3044\u53ce\u7e2e\u6a5f\u80fd\u306e\u4fdd\u305f\u308c\u305f\u5fc3\u4e0d\u5168\uff08HF\uff50EF\uff09\u306e\u79c1\u306e\u6cbb\u7642\u65b9\u91dd<\/p>\n<h4>Polyvascular Conference \u30002017.7.11\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u8239\u7530\u7adc\u4e00<br \/>\n\u30a4\u30f3\u30bf\u30fc\u30d9\u30f3\u30b7\u30e7\u30f3\u306e\u5408\u4f75\u75c7\u3068\u305d\u306e\u5bfe\u5fdc<\/p>\n<h4>\u5faa\u74b0\u5668\u967d\u5727\u547c\u5438\u30ab\u30f3\u30d5\u30a1\u30e9\u30f3\u30b9\u30002017.7.12\u3000(\u5c71\u5f62)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u5faa\u74b0\u5668\u9818\u57df\u306b\u304a\u3051\u308b\u7761\u7720\u547c\u5438\u969c\u5bb3\u306b\u3064\u3044\u3066\u201cSERVE-HR\u8a66\u9a13\u4ee5\u964d\u306eASV\u6cbb\u7642\u306e\u73fe\u72b6\u201d<\/p>\n<h4>\u7b2c\u4e8c\u56de\u4e09\u56fd\u5ce0PAH\u30ab\u30f3\u30d5\u30a1\u30e9\u30f3\u30b9\u30002017.7.18\uff08\u65b0\u6f5f\uff09<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u7fa4\u99ac\u5927\u5b66\u75c5\u9662\u306b\u304a\u3051\u308b\u80ba\u9ad8\u8840\u5727\u75c7\u8a3a\u7642\u306e\u53d6\u308a\u7d44\u307f<\/p>\n<h4>\u7b2c237\u56de\u4e00\u822c\u5b9a\u671f\u5065\u5eb7\u8a3a\u65ad\u306b\u304a\u3051\u308b\u80f8\u90e8\u30ec\u30f3\u30c8\u30b2\u30f3\u5199\u771f\u306e\u8aad\u5f71\u8b1b\u5ea72017.7.19\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\u8302\u6728\u3000\u5145<\/p>\n<h4>\u7b2c\uff12\u56de\u81e8\u5e8aSAS\u30d5\u30a9\u30fc\u30e9\u30e0\u30002017.7.20(\u4eac\u90fd)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u73fe\u72b6\u3067\u3044\u304b\u306bASV\u3092\u7528\u3044\u305f\u5fc3\u4e0d\u5168\u6cbb\u7642\u3092\u884c\u3046\u3079\u304d\u306a\u306e\u304b\uff1f<\/p>\n<h4>\u7b2c1\u56de\u5faa\u74b0\u5668\u75be\u60a3\u3092\u8003\u3048\u308b\u4f1a\u30002017.7.20\uff08\u9928\u6797\uff09<\/h4>\n<p>\u6e05\u6c34\u5cb3\u4e45<br \/>\n\u6297\u8840\u5c0f\u677f\u85ac\u3068\u6297\u51dd\u56fa\u85ac\u306e\u4e21\u65b9\u306b\u9069\u5fdc\u306e\u3042\u308b\u60a3\u8005\u3092\u3069\u3046\u3059\u308b\u304b\uff1f<\/p>\n<h4>\u7b2c14\u56de\u798f\u5cf6\u4e0d\u6574\u8108\u61c7\u8a71\u4f1a\u30002017.7.21\uff08\u798f\u5cf6\uff09<\/h4>\n<p>\u91d1\u53e4\u5584\u660e<br \/>\n\u623f\u5ba4\u7d50\u7bc0\u30ea\u30a8\u30f3\u30c8\u30ea\u30fc\u6027\u983b\u62cd\u306e\u6e29\u6545\u77e5\u65b0\uff0e<\/p>\n<h4>\u7b2c\uff14\u56deK-LEAD\u30002017.7.21(\u798f\u5ca1)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u5faa\u74b0\u5668\u9818\u57df\u306b\u304a\u3051\u308b\u7761\u7720\u547c\u5438\u969c\u5bb3\u306b\u3064\u3044\u3066\u201cSERVE-HF\u8a66\u9a13\u4ee5\u964d\u306eASV\u6cbb\u7642\u306e\u73fe\u72b6\u201d<\/p>\n<h4>Arrhythmia comference in Hiroshima 2017,\u30002017.7.22\uff08\u5e83\u5cf6\uff09<\/h4>\n<p>\u91d1\u53e4\u5584\u660e<br \/>\nsuperior slow pathway\u3068\u65b0\u3057\u3044\u623f\u5ba4\u7d50\u7bc0\u30ea\u30a8\u30f3\u30c8\u30ea\u30fc\u6027\u983b\u62cd\u306e\u63d0\u5531\uff0e<\/p>\n<h4>\u5317\u95a2\u6771\u5faa\u74b0\u5668\u30d5\u30a9\u30fc\u30e9\u30e0\u3000\u300c\u5de6\u5fc3\u8033\u9589\u9396\u8853\uff0b\u03b1\u300d2017.7.22\u3000\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u677e\u5c3e\u5f25\u679d<br \/>\n\u30d1\u30cd\u30eb\u30c7\u30a3\u30b9\u30ab\u30c3\u30b7\u30e7\u30f3<br \/>\nMultiple stent deformation case resulted in total occlusion<br \/>\n\u30d1\u30cd\u30eb\u30c7\u30a3\u30b9\u30ab\u30c3\u30b7\u30e7\u30f3<br \/>\nCase of acute coronary syndrome distressed with culprit determination and those thrombus management<\/p>\n<h4>\u5e73\u621029\u5e74\u5ea6\u3000\u7b2c2\u56deICT\u8b1b\u7fd2\u4f1a\u30002017.7.24\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\u8302\u6728\u3000\u5145<br \/>\n\u7d50\u6838\u306e\u9662\u5185\u611f\u67d3\u5bfe\u7b56<\/p>\n<h4>\u30d7\u30e9\u30a4\u30de\u30ea\u30fc\u30fb\u30b1\u30a2\u533b\u306e\u305f\u3081\u306eLecuture meeting\uff5e\u5faa\u74b0\u5668\u75be\u60a3\u306e\u660e\u65e5\u3092\u8003\u3048\u308b\uff5e\u30002017.7.25\uff08\u5510\u6d25\uff09<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u5faa\u74b0\u5668\u75be\u60a3\u306b\u304a\u3051\u308b\u30c8\u30d4\u30c3\u30afENGAGE trial\u3068\u79c1\u306e\u7814\u7a76<\/p>\n<h4>\u5faa\u74b0\u5668\u75be\u60a3\u306e\u660e\u65e5\u3092\u8003\u3048\u308b\u30002017.7.28\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u7b20\u9593\u3000\u5468<br \/>\n\u975e\u865a\u8840\u6027\u6025\u6027\u5fc3\u4e0d\u5168\u306b\u5bfe\u3059\u308bhANP\u7642\u6cd5\u306e\u5fc3\u81d3\u4ea4\u611f\u795e\u7d4c\u6d3b\u6027\u304a\u3088\u3073\u30a2\u30eb\u30c9\u30b9\u30c6\u30ed\u30f3\u6291\u5236\u306b\u53ca\u307c\u3059\u52b9\u679c<\/p>\n<h4>PCSK9 SUMMIT IN HOKKAIDO\u30002017.8.5\uff08\u672d\u5e4c\uff09<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\n\u30cf\u30a4\u30ea\u30b9\u30af\u60a3\u8005\u3078\u306e\u7a4d\u6975\u7684\u8102\u8cea\u4f4e\u4e0b\u7642\u6cd5\u306e\u610f\u7fa9<\/p>\n<h4>\u30d0\u30a4\u30a8\u30eb\u8b1b\u6f14\u4f1a\u30002017.8.6(\u6771\u4eac)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u30dd\u30d7\u30ed\u30b9\u30c6\u30ce\u30fc\u30eb\u6301\u7d9a\u9759\u6ce8\u60a3\u8005\u306b\u304a\u3051\u308b\u507d\u819c\u6027\u8178\u708e\uff12\u4f8b\u306e\u691c\u8a0e<\/p>\n<h4>Anticoagulants Seminar in \u592a\u7530\u30002017.8.8 (\u592a\u7530)<\/h4>\n<p>\u8239\u7530\u7adc\u4e00<br \/>\n\u5fc3\u8840\u7ba1\u30a4\u30d9\u30f3\u30c8\u306e\u6700\u524d\u7dda\u3000\uff5e\u6297\u51dd\u56fa\u7642\u6cd5\u306e\u73fe\u72b6\u3092\u8e0f\u307e\u3048\u3066\uff5e<\/p>\n<h4>\u7b2c21\u56deAdvanced cardiac imaging laboratory(ACIL)\u30002017.8.12<\/h4>\n<p>\u7b20\u9593\u3000\u5468<br \/>\n\u6838\u533b\u5b66\u6240\u898b\u304b\u3089\u307f\u305f\u30bf\u30b3\u30c4\u30dc\u578b\u5fc3\u7b4b\u75c7\u304a\u3088\u3073\u9451\u5225\u8a3a\u65ad\u306b\u3064\u3044\u3066<\/p>\n<h4>\u5e73\u6210\uff12\uff19\u5e74\u5ea6\u7fa4\u99ac\u770c\u6307\u5b9a\u96e3\u75c5\u7814\u4fee\u4f1a\u30002017.8.20(\u524d\u6a4b)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u96e3\u75c5\u6307\u5b9a\u306b\u304a\u3051\u308b\u5faa\u74b0\u5668\u30fb\u547c\u5438\u5668\u7cfb\u9818\u57df\u306b\u95a2\u3059\u308b\u4ee3\u8868\u7684\u306a\u75be\u60a3\u306e\u8a3a\u65ad<\/p>\n<h4>\u30d5\u30a1\u30a4\u30b6\u30fc\u793e\u5185\u8b1b\u6f14\u4f1a\u30002017.8.24\u3000(\u9ad8\u5d0e)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u65e5\u5e38\u8a3a\u7642\u306b\u6f5c\u3080\u80ba\u9ad8\u8840\u5727\u75c7\u306b\u3064\u3044\u3066<\/p>\n<h4>AFAblation Expert Meeting 2017\u30002017.9.1(\u6771\u4eac)<\/h4>\n<p>\u91d1\u53e4\u5584\u660e<br \/>\nsuperior slow pathway\u3068\u65b0\u3057\u3044\u623f\u5ba4\u7d50\u7bc0\u30ea\u30a8\u30f3\u30c8\u30ea\u30fc\u6027\u983b\u62cd\u306e\u63d0\u5531\uff0e<\/p>\n<h4>\u897f\u65b0\u5bbf\u4e0d\u6574\u8108\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9\u30002017.9.2\uff08\u6771\u4eac\uff09<\/h4>\n<p>\u91d1\u53e4\u5584\u660e<br \/>\nsuperior slow pathway\u3068\u65b0\u3057\u3044\u623f\u5ba4\u7d50\u7bc0\u30ea\u30a8\u30f3\u30c8\u30ea\u30fc\u6027\u983b\u62cd\u306e\u63d0\u5531\uff0e<\/p>\n<h4>\u7b2c30\u56de\u7fa4\u99ac\u770c\u51a0\u8840\u7ba1\u6cbb\u7642\u61c7\u8ac7\u4f1a\u30002017.9.2\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\uff11) \u5c0f\u91dd\u5c2d\u53f8\u3001\u677e\u5c3e\u5f25\u679d\u3001\u516b\u6728\u5b8f\u660e\u3001\u91d1\u4e95\u5b8f\u7fa9\u3001\u5ca9\u5d0e\u4fca\u5f25\u3001\u718a\u5009\u4e45\u592b<br \/>\nLAD\u672b\u68a2\u306b\u8840\u6813\u585e\u6813\u3092\u5408\u4f75\u3057\u305f\u3001LMT\u3092\u8cac\u4efb\u75c5\u5909\u3068\u3059\u308bACS\u306e\u4e00\u4f8b<\/p>\n<p>\uff12) \u91d1\u4e95\u674f\u5948\u3001\u5c0f\u91ce\u6d0b\u5e73\u3001\u9ad8\u677e\u5bdb\u4eba\u3001\u4e0a\u7530\u54f2\u4e5f\u3001\u9593\u6e15\u7531\u7d00\u592b\u3001\u4e95\u4e0a\u96c5\u6d69<br \/>\n\u53f3\u51a0\u52d5\u8108\u9589\u585e\u306b\u3088\u308b\u6025\u6027\u4e0b\u58c1\u5fc3\u7b4b\u6897\u585e\u306b\u5de6\u51a0\u52d5\u8108\u524d\u4e0b\u884c\u679d\u306e\u8d85\u9045\u767a\u6027\u30b9\u30c6\u30f3\u30c8\u8840\u6813\u75c7\u3092\u5408\u4f75\u3057\u3001\uff12\u679d\u540c\u6642\u9589\u585e\u3092\u304d\u305f\u3057\u305f1\u4f8b<\/p>\n<p>\uff13) \u6a0b\u53e3\u4eac\u4ecb\u3001\u5f8c\u85e4\u6176\u5927\u3001\u5409\u7530\u8c9e\u6e80\u3001\u4e2d\u5cf6\u6b63\u535a\u3001\u5c71\u5cb8\u9ad8\u5b8f<br \/>\n\uff13\u5206\u5c90\u5165\u53e3\u90e8\u72ed\u7a84\u3092\u4f34\u3046LMT-ACS\u75c5\u5909\u306b\u5bfe\u3057PCI\u65bd\u884c\u3057\u305f\u8d85\u9ad8\u9f62\u8005\u306e1\u4f8b<\/p>\n<p>\uff14) \u6a3a\u6fa4\u6d0b\u6cbb\u3001\u77f3\u7aaa\u592a\u4eba\u3001\u571f\u5c4b\u5bdb\u5b50\u3001\u8218\u91ce\u5229\u7d75\u5b50\u3001\u76f4\u7530\u5321\u5f66\u3001\u6238\u5cf6\u4fca\u4e00\u3001\u6c60\u7530\u58eb\u90ce\u3001\u4e2d\u91ce\u660e\u5f66\u3001\u798f\u7530\u4e08\u4e86<br \/>\nMedina\u201d0,1,0and1,0,1\u201d\u75c5\u5909\u306b\u3088\u308b\u4e0d\u5b89\u5b9a\u72ed\u5fc3\u75c7\u306b\u5bfe\u3057\u3066DCA-DCB\u3092\u65bd\u884c\u3057\u305f1\u4f8b<\/p>\n<p>\uff15) \u52a0\u85e4\u5bff\u5149\u3001\u77f3\u6a4b\u6d0b\u5e73\u3001\u7530\u6751\u672a\u592e\u3001\u5ead\u91ce\u548c\u751f\u3001\u6749\u6238\u7f8e\u52dd\u3001\u91d1\u5b50\u514b\u5df1<br \/>\n\u5de6\u51a0\u52d5\u8108\u4e3b\u5e79\u90e8\u5206\u5c90\u90e8\u306e\u5de6\u524d\u4e0b\u884c\u679d\u30b9\u30c6\u30f3\u30c8\u5185\u518d\u72ed\u7a84\u75c5\u5909\u3068\u5de6\u56de\u65cb\u679d\u75c5\u5909\u306b\u5bfe\u3057DCB\u3092\u65bd\u884c\u3057\u305f\u4e00\u4f8b<\/p>\n<h4>\u7b2c\uff16\u56de\u81e8\u5e8a\u8a66\u9a13\u306b\u95a2\u3059\u308b\u8b1b\u7fd2\u4f1a\u30002017.9.5(\u524d\u6a4b)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u6cbb\u7642\u300c\u5faa\u74b0\u5668\u9818\u57df\u306b\u304a\u3051\u308b\u65b0\u85ac\u958b\u767a\u306e\u52d5\u5411\u306b\u3064\u3044\u3066\u300d<\/p>\n<h4>Resolute Onyx\u30e9\u30a4\u30d6\u30002017.9.7\uff08\u6771\u4eac\uff09<\/h4>\n<p>\u8239\u7530\u7adc\u4e00<br \/>\n\u30e9\u30f3\u30c1\u30e7\u30f3\u30bb\u30df\u30ca\u30fc\u75c7\u4f8b\u8b1b\u6f14<\/p>\n<h4>\u5faa\u74b0\u5668\u5c02\u9580\u533b\u306b\u3088\u308b\u7cd6\u5c3f\u75c5\u6cbb\u7642\u3092\u8003\u3048\u308b\u4f1a\u30002017.9.8\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\uff11) \u6751\u7530\u3000\u8aa0<br \/>\nSGLT2\u963b\u5bb3\u85ac\u306b\u3088\u308bCPX\u3078\u306e\u5f71\u97ff(\u4eee)<\/p>\n<p>\uff12) \u690d\u7530\u54f2\u4e5f<br \/>\nSGLT2\u963b\u5bb3\u85ac\u306b\u3088\u308b\u5fc3\u81d3\u5468\u56f2\u6b7b\u4ea1\u3078\u306e\u5f71\u97ff\uff08\u4eee\uff09<\/p>\n<p>\uff13) \u7b20\u9593\u3000\u5468<br \/>\nSGLT2\u963b\u5bb3\u85ac\u306b\u3088\u308bRAAS\u3078\u306e\u5f71\u97ff<\/p>\n<h4>\u9759\u5ca1\u6771\u90e8\u8102\u8cea\u7570\u5e38\u75c7\u8b1b\u6f14\u4f1a\u30002017.9.8\uff08\u6cbc\u6d25\uff09<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\nLDL-C\u4f4e\u4e0b\u7642\u6cd5\u306e\u9032\u6b69\u3068\u6b8b\u3055\u308c\u3066\u3044\u308b\u8ab2\u984c<\/p>\n<h4>\u7b2c238\u56de\u4e00\u822c\u5b9a\u671f\u5065\u5eb7\u8a3a\u65ad\u306b\u304a\u3051\u308b\u80f8\u90e8\u30ec\u30f3\u30c8\u30b2\u30f3\u5199\u771f\u306e\u8aad\u5f71\u8b1b\u5ea7\u30002017.9.13(\u9ad8\u5d0e)<\/h4>\n<p>\u8302\u6728\u3000\u5145<\/p>\n<h4>Deep Dive in Hiroshima\uff5eDiabetes Mellitus &amp; Cardiovascular\uff5e\u30002017.9.15\uff08\u5e83\u5cf6\uff09<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\nSGLT2\u963b\u5bb3\u85ac\u306e\u5fc3\u814e\u75c7\u5019\u7fa4\u3078\u306e\u30d3\u30c3\u30b0\u30a4\u30f3\u30d1\u30af\u30c8<\/p>\n<h4>\u4f50\u6e21\u80ba\u9ad8\u8840\u5727\u75c7\u8b1b\u6f14\u4f1a\u30002017.9.15(\u4f50\u6e21)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u8eab\u8fd1\u306b\u6f5c\u3080\u80ba\u52d5\u8108\u6027\u80ba\u9ad8\u8840\u5727\u75c7\u306e\u8a3a\u65ad\u3068\u6cbb\u7642<\/p>\n<h4>\u7b2c7\u56deACHD\u6cbb\u7642\u7814\u7a76\u4f1a\u30002017.9.16(\u6771\u4eac)<\/h4>\n<p>\u53cd\u753a\u79c0\u7f8e<br \/>\n\u75c7\u4f8b\u691c\u8a0e<\/p>\n<h4>CV &amp; Diabetes Conference 2017.9.20(\u4f0a\u52e2\u5d0e)<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\nSGLT2\u963b\u5bb3\u85ac\u306e\u5fc3\u814e\u75c7\u5019\u7fa4\u3078\u306e\u30d3\u30c3\u30b0\u30a4\u30f3\u30d1\u30af\u30c8<\/p>\n<h4>\u7b2c\uff11\u56de\u9577\u5ca1PH Clinical Conference\u30002017.9.21(\u9577\u5ca1)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u5f53\u9662\u3067\u306e\u91cd\u75c7\u80ba\u9ad8\u8840\u5727\u75c7\u306e\u53d6\u308a\u7d44\u307f\uff5e\u30bb\u30ec\u30ad\u30b7\u30d1\u30b0\u306e\u4f7f\u7528\u7d4c\u9a13\u3092\u542b\u3081\u3066\uff5e<\/p>\n<h4>\u8108\u7ba1\u30af\u30e9\u30b9\u30bf\u30fc\u7814\u7a76\u8b1b\u6f14\u4f1a\u30002017.9.22(\u65ed\u5ddd)<\/h4>\n<p>\u78ef\u9054\u4e5f<br \/>\n\u6bdb\u7d30\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3092\u4ecb\u3059\u308b\u8102\u80aa\u9178\u4ee3\u8b1d\u306e\u30e1\u30ab\u30cb\u30ba\u30e0\u2015FABP4\/5\u304c\u5168\u8eab\u4ee3\u8b1d\u30fb\u5fc3\u81d3\u4ee3\u8b1d\u306b\u53ca\u307c\u3059\u5f71\u97ff<\/p>\n<h4>\u7b2c20\u56de\u7fa4\u99ac\u5fc3\u4e0d\u5168\u7814\u7a76\u4f1a\u30002017.9.26\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u4f50\u85e4\u4e07\u57fa\u4eba<br \/>\n\u9ad8\u9f62\u8005\u5fc3\u4e0d\u5168\u306e\u4e00\u4f8b<\/p>\n<h4>\u7b2c8\u56de\u900f\u6790\u60a3\u8005\u306e\u5faa\u74b0\u5668\u75be\u60a3\u3092\u8003\u3048\u308b\u4f1a\u30002017.10.5\uff08\u524d\u6a4b\uff09<\/h4>\n<p>1\uff09\u718a\u5009\u4e45\u592b<br \/>\nPAD\u306e\u75c5\u614b\u3068\u4e88\u5f8c\u306b\u304a\u3051\u308b\u814e\u6a5f\u80fd\u3068\u900f\u6790\u306e\u5f71\u97ff<\/p>\n<p>\uff12\uff09\u5009\u6797\u6b63\u5f66<br \/>\n\u900f\u6790\u60a3\u8005\u306e\u5fc3\u8840\u7ba1\u30ea\u30b9\u30af\u306e\u65b0\u305f\u306a\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc<\/p>\n<h4>\u7b2c9\u56de\u770c\u5317\u7cd6\u5c3f\u75c5\u30bb\u30df\u30ca\u30fc\u30002017.10.5\uff08\u65b0\u6f5f\uff09<\/h4>\n<p>\u7b20\u9593\u3000\u5468<br \/>\n\u5fc3\u4e0d\u5168\u6cbb\u7642\u3092\u518d\u8003\u3059\u308b<br \/>\n-SGLT2\u963b\u5bb3\u85ac\u304c\u3082\u305f\u3089\u3059\u5f71\u97ff\u3092\u542b\u3081\u3066-<\/p>\n<h4>\u5faa\u74b0\u5668\u75be\u60a3\u306e\u660e\u65e5\u3092\u8003\u3048\u308b\uff5e\u81f3\u9ad8\u306e\u30af\u30ea\u30cb\u30ab\u30eb\u30fb\u30a8\u30d3\u30c7\u30f3\u30b9\u3092\u8aad\u307f\u89e3\u304f\uff5e\u30002017.10.6\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u5927\u5c71\u5584\u662d<br \/>\nDPC\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u3092\u7528\u3044\u305f\u5faa\u74b0\u5668\u75ab\u5b66\u7814\u7a76<\/p>\n<h4>\u5faa\u74b0\u5668\u75be\u60a3\u306e\u660e\u65e5\u3092\u8003\u3048\u308b\u30002017.10.6(\u524d\u6a4b)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u81f3\u9ad8\u306e\u30af\u30ea\u30cb\u30ab\u30eb\u30fb\u30a8\u30d3\u30c7\u30f3\u30b9\u3092\u8aad\u307f\u89e3\u304f<\/p>\n<h4>\u967d\u5727\u547c\u5438\u7642\u6cd5\u7279\u5225\u8b1b\u6f14\u4f1a\u30002017.10.7(\u9577\u91ce)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u73fe\u72b6\u3067\u3044\u304b\u306bASV\u3092\u7528\u3044\u305f\u5fc3\u4e0d\u5168\u6cbb\u7642\u3092\u884c\u3046\u3079\u304d\u306a\u306e\u304b\uff1f<\/p>\n<h4>\u718a\u8c37\u5e02\u5185\u79d1\u533b\u5e2b\u4f1a\u5b66\u8853\u96c6\u4f1a\u30002017.10.10(\u718a\u8c37)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u73fe\u72b6\u3067\u3044\u304b\u306bASV\u3092\u7528\u3044\u305f\u5fc3\u4e0d\u5168\u6cbb\u7642\u3092\u884c\u3046\u3079\u304d\u306a\u306e\u304b\uff1f<\/p>\n<h4>\u6771\u6bdb\u6297\u51dd\u56fa\u7642\u6cd5\u5b66\u8853\u8b1b\u6f14\u4f1a\u30002017.10.10\uff08\u592a\u7530\uff09<\/h4>\n<p>\u4e45\u4fdd\u7530\u4fee\u5e73<br \/>\n\u5fc3\u623f\u7d30\u52d5\u8a3a\u7642\u306e\u30de\u30a4\u30c8\u30ec\u30f3\u30c9<\/p>\n<h4>\u7b2c22\u56de\u3000\u5e02\u6c11\u516c\u958b\u8b1b\u5ea7\u30002017.10.10\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\u8302\u6728\u3000\u5145<br \/>\n\u80ba\u304c\u3093 \u3000\u3000\u80ba\u304c\u3093\u306f\u5897\u3048\u3066\u3044\u307e\u3059<br \/>\n\u300e\u4eca\u5897\u3048\u3066\u3044\u308b\u304c\u3093\u3068\u6e1b\u3063\u3066\u3044\u308b\u304c\u3093\u300f \u300e\u306a\u305c\uff1f\u300f<\/p>\n<h4>\u5b9f\u5730\u533b\u5bb6\u30df\u30fc\u30c6\u30a3\u30a4\u30b0\u30002017.10.11\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\u7b20\u9593\u3000\u5468<br \/>\n\u5fc3\u4e0d\u5168\u65e5\u5e38\u8a3a\u7642\u306b\u753b\u50cf\u8a3a\u65ad\u3092\u6d3b\u304b\u3059<\/p>\n<h4>\u7b2c239\u56de\u4e00\u822c\u5b9a\u671f\u5065\u5eb7\u8a3a\u65ad\u306b\u304a\u3051\u308b\u80f8\u90e8\u30ec\u30f3\u30c8\u30b2\u30f3\u5199\u771f\u306e\u8aad\u5f71\u8b1b\u5ea7 2017.10.16(\u9ad8\u5d0e)<\/h4>\n<p>\u8302\u6728\u3000\u5145<\/p>\n<h4>\u524d\u6a4b\u5e02\u85ac\u5264\u5e2b\u4f1a\u7814\u7a76\u4f1a\u30002017.10.17(\u524d\u6a4b)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u80ba\u9ad8\u8840\u5727\u75c7\u3068\u9759\u8108\u8840\u6813\u75c7\u306b\u3064\u3044\u3066<\/p>\n<h4>\u9928\u6797\u539a\u751f\u75c5\u9662\u8b1b\u6f14\u4f1a\u30002017.10.20(\u9928\u6797)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u8eab\u8fd1\u306b\u6f5c\u3080\u80ba\u52d5\u8108\u6027\u80ba\u9ad8\u8840\u5727\u75c7\u306e\u8a3a\u65ad\u3068\u6cbb\u7642<\/p>\n<h4>\u7b2c6\u56de\u533b\u7642\u5f93\u4e8b\u8005\u306e\u305f\u3081\u306e\u30ea\u30a6\u30de\u30c1\u8b1b\u6f14\u4f1a\u30002017.10.20\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\u8302\u6728\u3000\u5145<br \/>\n\u95a2\u7bc0\u30ea\u30a6\u30de\u30c1\u306b\u5408\u4f75\u3059\u308b\u547c\u5438\u5668\u75be\u60a3\u306e\u81e8\u5e8a<\/p>\n<h4>\u5faa\u74b0\u30fb\u4ee3\u8b1d\u30fb\u708e\u75c7\u30fb\u75c5\u614b\u7814\u7a76\u30bb\u30df\u30ca\u30fc\u30002017.10.20\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u5c0f\u677f\u6a4b\u7d00\u901a<br \/>\nDOAC\u3092\u7528\u3044\u305fVTE\u6cbb\u7642<\/p>\n<h4>\u81e8\u5e8a\u533b\u306e\u305f\u3081\u306e\u7d71\u8a08\u30bb\u30df\u30ca\u30fc\uff5e\u8a3a\u7642\u306e\u4e2d\u3067\u51fa\u4f1a\u3046\u7d71\u8a08\u304b\u3089\u7814\u7a76\u8a08\u753b\u307e\u3067\uff5e\u30002017.10.21(\u524d\u6a4b)<\/h4>\n<p>\u85e4\u7530\u6674\u5eb7<br \/>\n\u8cea\u554f\u7968\u3092\u7528\u3044\u305f\u7814\u7a76\u306e\u89e3\u6790\u624b\u6cd5<\/p>\n<h4>\u4f0a\u52e2\u5d0e\u8840\u7ba1\u30e9\u30dc\u7814\u7a76\u4f1a\u30002017.10.23\uff08\u4f0a\u52e2\u5d0e\uff09<\/h4>\n<p>\u795e\u5c71\u3000\u5b8f<br \/>\nCHADS2\u30671\u70b9\u4ee5\u4e0b\u3042\u308b\u3044\u306f\u8e8a\u8e87\u3057\u305f\u304f\u306a\u308b\u5f8c\u671f\u9ad8\u9f62\u8005\u306e\u6297\u51dd\u56fa\u7642\u6cd5\u3092\u3069\u3046\u3059\u308b\u304b<\/p>\n<h4>Gunma FC TRIBE 2017.10.24\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u8239\u7530\u7adc\u4e00<br \/>\n\u30c7\u30d0\u30a4\u30b9\u3092\u8003\u3048\u308b<\/p>\n<h4>\u7b2c6\u56deGunma Prevent\u3000\uff08\u524d\u6a4b\uff09\u30002017.10.25<\/h4>\n<p>\u5b89\u9054\u3000\u4ec1<br \/>\n\u51a0\u52d5\u8108\u8fd1\u533b\u90e8\u6709\u610f\u72ed\u7a84\u75c5\u5909\u3092\u6709\u3059\u308b\u60a3\u8005\u306b\u5bfe\u3059\u308b\u5fc3\u81d3\u30ea\u30cf\u30d3\u30ea\u30c6\u30fc\u30b7\u30e7\u30f3\u306eCPX\u306e\u30d1\u30e9\u30e1\u30fc\u30bf\u4e0a\u306e\u52b9\u679c<\/p>\n<h4>\u5ca1\u5c71PH\u30bb\u30df\u30ca\u30fc\u30002017.10.27(\u5ca1\u5c71)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u75c7\u4f8b\u5831\u544a<\/p>\n<h4>PE\/DVT Forum\uff0d\u6297\u51dd\u56fa\u7642\u6cd5\u306e\u9032\u5c55\u3068\u6b8b\u3055\u308c\u305f\u8ab2\u984c\u2015\u30002017.10.29\uff08\u6771\u4eac\uff09<\/h4>\n<p>\u5c0f\u677f\u6a4b\u7d00\u901a<br \/>\nPE\/DVT\u6cbb\u7642\u6a19\u6e96\u5316\u3092\u3081\u3056\u3057\u3066\u30fc\u6cbb\u7642\u30d1\u30b9\u4f5c\u6210\u306e\u8a66\u307f\u30fc<\/p>\n<h4>\u57fc\u7389\u6771\u90e8\u5730\u533aCOPD\u5b66\u8853\u8b1b\u6f14\u4f1a\u30002017.10.31\uff08\u8d8a\u8c37\uff09<\/h4>\n<p>\u9752\u6728\u5eb7\u5f18<br \/>\nCOPD\u6cbb\u7642\u306b\u304a\u3051\u308b\u51e6\u65b9\u306e\u30b3\u30c4\u3068\u5438\u5165\u652f\u63f4<\/p>\n<h4>throbmosis Conference\u30002017.10.31(\u5b87\u90fd\u5bae)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u8840\u6813\u75c7\u30ea\u30a2\u30eb\u30ef\u30fc\u30eb\u30c9\u30c7\u30fc\u30bf\u30fc\u304b\u3089\u306e\u30e1\u30c3\u30bb\u30fc\u30b8\u3000Current and Future Directions<\/p>\n<h4>\u7b2c13\u56de\u7fa4\u99ac\u548c\u6f22\u8a3a\u7642\u30d5\u30a9\u30fc\u30e9\u30e0\u3000\uff12\uff10\uff11\uff17.\uff11\uff11\uff0e\uff12(\u524d\u6a4b)<\/h4>\n<p>\uff11) \u5c0f\u548c\u702c\u6842\u5b50\u5148\u751f<br \/>\n\u5730\u57df\u533b\u7642\u3068\u7dcf\u5408\u8a3a\u7642<\/p>\n<p>\uff12) \u4f50\u85e4\u6d69\u5b50\u5148\u751f<br \/>\n\u5730\u57df\u533b\u7642\u306b\u304a\u3051\u308b\u6f22\u65b9\u85ac\u306e\u5fc5\u8981\u6027<\/p>\n<p>\uff13) \u795e\u7530\u4eab\u52c9\u5148\u751f<br \/>\n\u5730\u57df\u533b\u7642\u3068\u56fd\u969b\u6027<\/p>\n<h4>\u9759\u8108\u8840\u6813\u585e\u6813\u75c7\u3092\u8003\u3048\u308b\u4f1a\u30002017.11.7(\u6df1\u8c37)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u80ba\u9ad8\u8840\u5727\u75c7\u3068\u9759\u8108\u8840\u6813\u585e\u6813\u75c7<\/p>\n<h4>\u8102\u8cea\u7570\u5e38\u75c7Expert Meeting in Hokkaido\u30002017.11.4\uff08\u672d\u5e4c\uff09<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\n\u52d5\u8108\u786c\u5316\u75c7\u75be\u60a3\u4e88\u9632\u306eUp to date<\/p>\n<h4>\u7b2c22\u56deAdvanced cardiac imaging laboratory(ACIL)\u30002017.11.4\uff08\u6771\u4eac\uff09<\/h4>\n<p>\u7b20\u9593\u3000\u5468<br \/>\n\u5fc3\u4e0d\u5168\u306b\u304a\u3051\u308bMIBG\u5fc3\u7b4b\u30b7\u30f3\u30c1\u30b0\u30e9\u30d5\u30a3\u306e\u6709\u7528\u6027<\/p>\n<h4>\u7b2c\uff13\u56deCardiac Biomarker\u7814\u7a76\u4f1a\u30002017.11.4\uff08\u54c1\u5ddd\uff09<\/h4>\n<p>\u5c0f\u677f\u6a4b\u7d00\u901a<br \/>\n\u5fc3\u4e0d\u5168\u306b\u304a\u3051\u308b\u30ea\u30d0\u30fc\u30b9\u30fb\u30ea\u30e2\u30c7\u30ea\u30f3\u30b0\u2015\u305d\u306e\u30e1\u30ab\u30cb\u30ba\u30e0\u3068\u6cbb\u7642\u4ecb\u5165\u2015<\/p>\n<h4>\u7b2c8\u56de\u9577\u5d0e\u5faa\u74b0\u5668\u753b\u50cf\u7814\u7a76\u4f1a\u30002017.11.7(\u9577\u5d0e)<\/h4>\n<p>\u7b20\u9593\u3000\u5468<br \/>\n\u65e5\u5e38\u8a3a\u7642\u306b\u304a\u3051\u308b\u5fc3\u81d3\u4ea4\u611f\u795e\u7d4c\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u306e\u6709\u7528\u6027<br \/>\n-\u5fc3\u81d3\u6838\u533b\u5b66\u691c\u67fb\u304b\u3089\u306e\u30a2\u30d7\u30ed\u30fc\u30c1-<\/p>\n<h4>\u8102\u8cea\u7570\u5e38\u75c7\u6cbb\u7642\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9\u3000In\u3000\u4f0a\u52e2\u5d0e\u4f50\u6ce2\u30002017.11.8(\u4f0a\u52e2\u5d0e)<\/h4>\n<p>\u5009\u6797\u6b63\u5f66\u5148\u751f<br \/>\n\u52d5\u8108\u786c\u5316\u6027\u75be\u60a3\u4e88\u9632\u306eUp to date<\/p>\n<h4>\u7b2c71\u56de\u56fd\u7acb\u75c5\u9662\u7dcf\u5408\u533b\u5b66\u4f1a2017.11.10\uff08\u9ad8\u677e\uff09<\/h4>\n<p>\u4f50\u85e4\u9ebb\u91cc\uff0c\u4e0a\u91ce\u3000\u5b66\uff0c\u5927\u5cf6\u4e00\u771f\uff0c\u9234\u6728\u96c5\u6587\uff0c\u6e05\u6c34\u96c4\u81f3\uff0c\u8302\u6728\u3000\u5145<br \/>\n\u5f53\u9662\u306b\u304a\u3051\u308b\u8aa4\u56a5\u6027\u80ba\u708e\u306e\u81e8\u5e8a\u7684\u691c\u8a0e<\/p>\n<h4>\u7b2c240\u56de\u4e00\u822c\u5b9a\u671f\u5065\u5eb7\u8a3a\u65ad\u306b\u304a\u3051\u308b\u80f8\u90e8\u30ec\u30f3\u30c8\u30b2\u30f3\u5199\u771f\u306e\u8aad\u5f71\u8b1b\u5ea7\u30002017.11.13\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\u8302\u6728\u3000\u5145<\/p>\n<h4>Stroke Medical Cooperation 2017\u30002017.11.15(\u9ad8\u5d0e)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u9759\u8108\u8840\u6813\u585e\u6813\u75c7\u306e\u8a3a\u65ad\u3068\u6cbb\u7642- Current and Future Directions-<\/p>\n<h4>\u7b2c34\u56de\u5b89\u82b8\u5730\u533a\u5faa\u74b0\u5668\u30d5\u30a9\u30fc\u30e9\u30e0\u30002017.11.17(\u5e83\u5cf6)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u73fe\u72b6\u3067\u3044\u304b\u306bASV\u3092\u7528\u3044\u305f\u5fc3\u4e0d\u5168\u6cbb\u7642\u3092\u884c\u3046\u3079\u304d\u306a\u306e\u304b\uff1f<\/p>\n<h4>\u9032\u5316\u3059\u308b\u7cd6\u5c3f\u75c5\u6cbb\u7642\uff5e\u5faa\u74b0\u5668\u77f3\u306e\u8996\u70b9\u304b\u3089\u8003\u3048\u308b\uff5e2017.11.18\uff08\u6a2a\u6d5c\uff09<\/h4>\n<p>\uff11) \u3000\u5009\u6797\u6b63\u5f66<br \/>\n\u5faa\u74b0\u5668\u5185\u79d1\u533b\u304b\u3089\u898b\u305f\u7cd6\u5c3f\u75c5\u6cbb\u7642\u306b\u3064\u3044\u3066<\/p>\n<p>\uff12) \u3000\u5009\u6797\u6b63\u5f66<br \/>\n\u30d1\u30cd\u30eb\u30c7\u30a3\u30b9\u30ab\u30c3\u30b7\u30e7\u30f3<\/p>\n<h4>\u25cf\u81e8\u5e8a\u533b\u306e\u305f\u3081\u306e\u7d71\u8a08\u30bb\u30df\u30ca\u30fc\uff5e\u8a3a\u7642\u306e\u4e2d\u3067\u51fa\u4f1a\u3046\u7d71\u8a08\u304b\u3089\u7814\u7a76\u8a08\u753b\u307e\u3067\uff5e2017.11.18\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u85e4\u7530\u6674\u5eb7<br \/>\n\u30ce\u30f3\u30d1\u30e9\u30e1\u30c8\u30ea\u30c3\u30af\u306e\u89e3\u6790\u624b\u6cd5<\/p>\n<h4>Cardiovascular forum in UTSUNOMIYA 2017 2017.11.22(\u5b87\u90fd\u5bae)<\/h4>\n<p>\u5009\u6797\u6b63\u5f66<br \/>\n\u52d5\u8108\u786c\u5316\u6027\u75be\u60a3\u4e88\u9632\u306eUp to date<\/p>\n<h4>\u6771\u4fe1\u30a8\u30ea\u30a2\u3000VTE\u61c7\u8a71\u4f1a\u30002017.11.22\uff08\u4f50\u4e45\uff09<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u9759\u8108\u8840\u6813\u585e\u6813\u75c7\u306e\u8a3a\u65ad\u3068\u6cbb\u7642- Current and Future Directions-<\/p>\n<h4>\u7b2c10\u56de\u7fa4\u99ac\u30af\u30ea\u30c6\u30a3\u30ab\u30eb\u30b1\u30a2\u7814\u7a76\u4f1a\u30002017.11.25\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\u8239\u7530\u7adc\u4e00<br \/>\nBasic Lectures<br \/>\n\u865a\u8840\u6027\u5fc3\u75be\u60a3<\/p>\n<h4>\u3088\u3064\u8449\u306e\u4f1a\uff08\u80ba\u9ad8\u8840\u5727\u75c7\u60a3\u8005\u4f1a\uff09\u30002017.11.26(\u524d\u6a4b)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u8eab\u8fd1\u306b\u6f5c\u3080\u80ba\u52d5\u8108\u6027\u80ba\u9ad8\u8840\u5727\u75c7\u306e\u8a3a\u65ad\u3068\u6cbb\u7642<\/p>\n<h4>\u9759\u8108\u8840\u6813\u585e\u6813\u75c7\u3000\u8a3a\u65ad\u30fb\u6cbb\u7642\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9\u30002017.11.27(\u65ed\u5ddd)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u9759\u8108\u8840\u6813\u585e\u6813\u75c7\u306e\u8a3a\u65ad\u3068\u6cbb\u7642- Current and Future Directions-<\/p>\n<h4>\u5e73\u621029\u5e74\u5ea6\u3000\u9662\u5185ICT\u8b1b\u6f14\u4f1a\u30002017.11.27\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\u8302\u6728\u3000\u5145<br \/>\n\u30a4\u30f3\u30d5\u30eb\u30a8\u30f3\u30b6\u5bfe\u7b56<\/p>\n<h4>\u5f18\u524d\u30a2\u30d6\u30ec\u30fc\u30b7\u30e7\u30f3\u52c9\u5f37\u4f1a\u30002017.11.28\uff08\u5f18\u524d\uff09<\/h4>\n<p>\u91d1\u53e4\u5584\u660e<br \/>\nSuperior slow pathway\u3068\u65b0\u3057\u3044\u623f\u5ba4\u7d50\u7bc0\u30ea\u30a8\u30f3\u30c8\u30ea\u30fc\u6027\u983b\u62cd\u306e\u63d0\u5531<\/p>\n<h4>Scientific symposium in Gunma\u30002017.11.29\u3000(\u524d\u6a4b)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\nA case of severe pulmonary arterial hypertension with MCTD<\/p>\n<h4>\u7b2c\uff16\u56deCirculation Frontier in Gunma\u30002017.12.1\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u5f8c\u85e4\u6176\u5927<br \/>\n\u51a0\u52d5\u8108\u75be\u60a3\u306e\u6b8b\u4f59\u30ea\u30b9\u30af\u306e\u306a\u3044\u60a3\u8005\u306bPCSK-9\u963b\u5bb3\u85ac\u3092\u6295\u4e0e\u3057\u305f\uff11\u4f8b<\/p>\n<h4>\u7fa4\u99ac\u5fc3\u81d3\u6838\u533b\u5b66\u75c7\u4f8b\u691c\u8a0e\u4f1a\u30002017.12.2\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u7b20\u9593\u3000\u5468<br \/>\n\u5fc3\u81d3\u6838\u533b\u5b66\u691c\u67fb\u306e\u6700\u65b0\u306e\u8a71\u984c<\/p>\n<h4>\u764c\u3068\u8840\u6813\u75c7\u7814\u7a76\u4f1a2017\u30002017.12.4\uff08\u65b0\u6f5f\uff09<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u9759\u8108\u8840\u6813\u585e\u6813\u75c7\u306e\u8a3a\u65ad\u3068\u6cbb\u7642- Current and Future Directions-<\/p>\n<h4>\u6df1\u8c37\u5bc4\u5c45\u533b\u5e2b\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a\u30002017.12.6 \uff08\u6df1\u8c37\uff09<\/h4>\n<p>\u8239\u7530\u7adc\u4e00<br \/>\n\u30a4\u30f3\u30bf\u30fc\u30d9\u30f3\u30b7\u30e7\u30f3\u6700\u524d\u7dda\u3000\uff5e\u5faa\u74b0\u5668\u5185\u79d1\u533b\u306e\u8003\u3048\u308b\u6297\u51dd\u56fa\u7642\u6cd5\u3092\u542b\u3081\u3066\uff5e<\/p>\n<h4>\u4e0d\u6574\u8108\u30a2\u30ab\u30c7\u30df\u30fc2017\uff5eAdvanced\uff5e\u30002017.12.8\uff08\u5ca1\u5c71\uff09<\/h4>\n<p>\u91d1\u53e4\u5584\u660e<br \/>\nSuperior slow pathway\u3068\u65b0\u3057\u3044\u623f\u5ba4\u7d50\u7bc0\u30ea\u30a8\u30f3\u30c8\u30ea\u30fc\u6027\u983b\u62cd\u306e\u63d0\u5531<\/p>\n<h4>Advanced Medical Technology Seminar\u30002017.12.12(\u524d\u6a4b)<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u6700\u8fd1\u306eVTE\u6cbb\u7642\u306b\u3064\u3044\u3066<\/p>\n<h4>ADVANCED SEMINAR in GUNMA\u30002017.12.15\uff08\u524d\u6a4b\uff09<\/h4>\n<p>\u5ead\u524d\u91ce\u83ca\u5148\u751f<br \/>\n\u9ad8\u9f62\u8005\u306b\u6c42\u3081\u3089\u308c\u308b\u6297\u51dd\u56fa\u7642\u6cd5UP TO DATE<\/p>\n<h4>\u8840\u6813\u585e\u6813\u75c7\u30d5\u30a9\u30fc\u30e9\u30e0 in \u6e0b\u5ddd\u30002017.12.19\u3000\uff08\u6e0b\u5ddd\uff09<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u9759\u8108\u8840\u6813\u585e\u6813\u75c7\u3000Up to Date<\/p>\n<h4>\u7b2c200\u56de\u5e02\u6c11\u5065\u5eb7\u533b\u5b66\u8b1b\u5ea7\u30002017.12.20\uff08\u9ad8\u5d0e\uff09<\/h4>\n<p>\u8302\u6728\u3000\u5145<br \/>\n\u9ad8\u9f62\u8005\u80ba\u708e\u3068\u305d\u306e\u4e88\u9632<\/p>\n<h4>\u62c5\u304c\u3093\u60a3\u8005\u306e\u30c8\u30fc\u30bf\u30eb\u30de\u30cd\u30fc\u30b8\u30e1\u30f3\u30c8\u30002017.12.27\uff08\u6cbc\u7530\uff09<\/h4>\n<p>\u9ad8\u9593\u5178\u660e<br \/>\n\u9759\u8108\u8840\u6813\u585e\u6813\u75c7\u3000Up to Date<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u7b2c18\u56deAdvanced cardiac imaging laboratory(ACIL) 2017.1.7\uff08\u6771\u4eac\uff09 \u7b20\u9593\u3000\u5468 \u5fc3\u4e0d\u5168\u306b\u304a\u3051\u308bMIBG\u306e\u6709\u7528\u6027 \u7b2c232\u56de\u4e00\u822c\u5b9a\u671f\u5065\u5eb7\u8a3a\u65ad\u306b\u304a\u3051\u308b\u80f8\u90e8\u30ec\u30f3\u30c8\u30b2\u30f3\u5199\u771f\u306e\u8aad\u5f71\u8b1b [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":299,"menu_order":61,"comment_status":"closed","ping_status":"closed","template":"tpl_results.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-301","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/pages\/301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=301"}],"version-history":[{"count":3,"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/pages\/301\/revisions"}],"predecessor-version":[{"id":305,"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/pages\/301\/revisions\/305"}],"up":[{"embeddable":true,"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/pages\/299"}],"wp:attachment":[{"href":"https:\/\/gucvmed.med.gunma-u.ac.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}